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IMPACT OF DIFFERENTIATION STATUS OF KIDNEY PROGENITORS IN WILMS
TUMOR DEVELOPMENT

Le Huang, M.S.

Advisory Professor: Vicki Huff, Ph.D.

Wilms tumor is one of the most common solid tumors in children. It is an embryonic
cancer of the kidney and is thought to arise from undifferentiated renal mesenchyme.
However, the differentiation status of cells in the mesenchyme that can give rise to Wilms
tumors is unknown. Gene expression analysis of a large panel of Wilms tumor patients has
identified different subsets of Wilms tumors that are distinct in their clinical outcomes and
gene expression signatures. These subsets express specific genes that correspond to
different stages of differentiation during renal development, suggesting that Wilms tumors
may arise from transformed cells at different states of differentiation. Wilms tumors are
genetically heterogeneous, which can also affect the tumor biology and pathology. To test
whether cells at different states of differentiation were tumorigenic, we used progenitor celltype-specific Cre to introduce mutations of Wilms Tumor gene 1 (Wt1) or β-catenin into fetal
kidney cells in a progenitor-specific manner. We found that the nephron progenitors but not
the stroma progenitors were able to give rise to Wilms tumors and that the different types of
mutations introduced into nephron progenitor cells resulted in Wilms tumors with differing
histology and expression of developmentally regulated genes. Also, to investigate the
mechanisms by which WT1 mutations cause a predisposition to Wilms tumors, we studied
the in vivo effects of Wt1 ablation in different renal progenitor cells. We found that Wt1
ablation in stroma progenitors did not affect nephrogenesis but that Wt1 is required for
nephron progenitors to undergo mesenchyme to epithelia transition.
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Chapter 1: Introduction
1.1 Wilms tumors (WT)
Wilms tumor, also named nephroblastoma, is one of the most common solid tumors in
children. It is a pediatric cancer of kidney and affects 1 in every 10,000 live births in North
America (Beckwith, 1983). It was first recognized by the German surgeon Max Wilms in
1899 in a 3-year-old patient. The average age of tumor onset for Wilms tumor is 38 months
old in the U.S., and the typical symptoms are growth of an abdominal mass and pain
(Breslow et al., 1993). The tumors are often in one kidney, with less than 5% occurring in
both kidneys (Breslow et al., 1993). Wilms tumors rarely metastasize but if they do, they
metastasize mainly to the lungs, lymph nodes, bones and brain (NLM, 2015). Wilms tumor
patients are usually treated with a combination of surgery and chemotherapy, and if the
tumor is at an advanced stage, radiation therapy is also applied. The 5-year survival rate is
approximately 90% (Smith et al., 2014). Despite the fact that 90% Wilms tumors are curable,
those who survive their tumors suffer from side effects of chemotherapy and radiation
therapy. Understanding the etiology of Wilms tumor will help in the development of improved
treatment with fewer side effects.
Wilms tumors are usually encapsulated within a fibrotic pseudocapsule, separated from
the adjacent normal kidney. The precursor lesions of WT are known as nephrogenic rests
(Beckwith, 1998). Nephrogenic rests are nodules of blastemal cells, which are mesenchymal
cells arrested at an early stage of differentiation during kidney development (Beckwith,
1998). Genetic studies of Wilms tumors have shown that the nephrogenic rests and Wilms
tumors share the same mutations, however, additional mutations are found in Wilms tumors,
suggesting a sequential progression from the nephrogenic rest to Wilms tumor (Fukuzawa et
al., 2007). When second genetic mutations or oncogenic events occur within the
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nephrogenic rests, the lesional cells may be transformed and clonal expansion of such cells
can progress to the development of Wilms tumors.
The typical histology of Wilms tumor is triphasic, consisting of undifferentiated blastemal
elements as well as differentiating epithelial and stromal elements (Beckwith and Palmer,
1978). Wilms tumors are heterogeneous, with varying degrees of each element. Abnormally
differentiated elements such as myogenic, chondrogenic, osteogenic or adipogenic cells can
also be found in some of the Wilms tumors. Histologically, Wilms tumors recapitulate the
development of embryonic kidney (Fig. 1.1). The blastemal elements in the tumor appear
like the undifferentiated metanephric mesenchyme of the developing kidney, whereas the
epithelial elements resemble the differentiating epithelial structures after mesenchyme to
epithelial transition, including comma-shaped body, S-shaped body, tubules and glomeruli
(Beckwith, 1983). Although different histologic components are present in Wilms tumors,
studies have shown that these components shared the same genetic changes, suggesting
that Wilms tumor is a clonal expansion of the transformed undifferentiated mesenchymal cell
that can potentially differentiate to epithelial, stromal or ectopic elements (Zhuang et al.,
1997) (Guertl et al., 2006).
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Figure 1.1 Wilms tumor histologically recapitulates fetal kidney

(A) Human fetal kidney. (B) Human Wilms tumor. B, S, and E designate
blastemal, epithelial and stromal components, respectively.
Images are from website http://www.humpath.com/spip.php?article5075

3

1.2 Kidney development
To understand Wilms tumorigenesis, it is important to understand the process of kidney
development (Fig. 1.2). Kidney development starts with the formation of the Wolffian duct
and the nephrogenic cord from the intermediate mesenchyme (Davidson, 2008). The
nephrogenic cord generates the pronephros, mesonephros and metanephros, with the first
two degenerating during mammalian embryonic development. The Wolffian duct extends the
ureteric buds to invade the metanephric mesenchyme, and at the same time, the
metanephric mesenchyme signals to the ureteric buds and induces them to branch
iteratively. In response, the ureteric buds stimulate the metanephric mesenchyme to
differentiate. The metanephric mesenchyme first condenses around the tips of the ureteric
buds to form the cap mesenchyme (CM). Then the CM undergoes mesenchyme to epithelial
transition (MET) and forms the renal vesicles (RV) proximal to the ureteric buds. The
resulting renal vesicles further epithelialize and connect to the ureteric buds to form the
comma-shaped bodies and the S-shaped bodies. The S-shaped bodies are segmented and
differentiate, together with the ureteric buds, to form the fully mature nephrons, the
functional units of the kidney, which include the proximal tubules, distal tubules, loops of
Henle and glomeruli (Davidson, 2008).
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Figure 1.2 Diagram of kidney development
(A) Metanephric kidney development starts with ureteric bud (UB) invasion into
metanephric mesenchyme. (B & C) UB branches repeatedly and elongates the
stalk. (D) Metanephric mesenchyme condenses around the UB tip. (E & F)
The mesenchyme undergoes mesenchyme to epithelial transition and
differentiates to form renal vesicle, comma-shaped body and S-shaped body.
(G) The S-shaped body connects to the UB and further differentiates and
segments to form the nephron.
Image is from Review: Shah, M.M., Sampogna, R.V., Sakurai, H., Bush, K.T., and Nigam, S.K. (2004). Branching
morphogenesis and kidney disease. Development 131, 1449-1462.
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1.3 Kidney progenitor compartments
During kidney development, there are two major types of progenitors in the
undifferentiated metanephric mesenchyme: the stromal progenitor and the nephron
progenitor (Fig. 1.3 A) (Mugford et al., 2009) (Self et al., 2006) (Kobayashi et al., 2014). The
specification of the stromal progenitor and the nephron progenitor starts from the common
Osr1-expressing precursor cells in intermediate mesenchyme and metanephric
mesenchyme (MM) (Mugford et al., 2008b).
The stromal progenitors are at the periphery of the metanephric mesenchyme and
surround the nephron progenitors. They specifically express FOXD1 and give rise to the
interstitium, pericytes, mesangial cells, and smooth muscle cells in the kidney (Humphreys
et al., 2010; Kobayashi et al., 2014).
The nephron progenitors reside in the cap mesenchyme (CM) that surrounds the tips of
the ureteric buds (Fig. 1.3) (Self et al., 2006). One proposal is that the CM contains
heterogeneous cell populations due to the different expression pattern of transcription
factors and its spatial location surrounded by different growth factors, ligands and cell types
(Hendry et al., 2011). As defined by gene expression pattern, the CM contains two
subpopulations, the uninduced and the induced CM (Mugford et al., 2009). Cells within the
uninduced CM express both markers CITED1 and SIX2. The CITED1+ SIX2+ cells have
been shown to be the self-renewing population, and they resist the differentiation-inducing
signals from ureteric buds (Brown et al., 2013). However, the induced CM expresses SIX2
but not CITED1 (CITED1- SIX2+) and starts to differentiate and undergo MET to form RVs
(Brown et al., 2013; Mugford et al., 2009). The nephron progenitors (SIX2+ or CITED1+) give
rise to the majority of the cells in the nephrons, including epithelial cells in the glomeruli,
proximal tubules, distal tubules and loop of Henle (Kobayashi et al., 2008). In situ
hybridization of whole mount embryonic kidneys with transcription factors identified
differences in the gene expression patterns between the uninduced CM and the induced CM
6

(Mugford et al., 2009). The uninduced CITED1+ SIX2+ cells express genes Meox1 and Dpf3,
while the induced CITED1- SIX2+ cells express genes Wnt4, Fgf8, Pax8, Lhx1 and Pea3,
suggesting different transcription programs between the uninduced and induced CM cells
(Mugford et al., 2009).
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Ureteric
bud

Foxd1+: stromal progenitor
Six2+: CM
Cited1+: uninduced CM

Figure 1.3 Diagram of kidney progenitor compartments in mesenchyme and
interactions of proteins between CM, UB and stromal.
(A) The Foxd1+ stromal progenitors are located outside the CM and produce
interstitium, pericyte and mesangial cells etc. The uninduced CM expresses
both Cited1 and Six2, while the induced CM is Cited1- Six2+. The nephron
progenitors in the CM give rise to the majority of the cells in the nephron.
(B) Diagram of the key genes in each compartment in the nephrogenic zone and
the interactions between the compartments of CM, UB and stromal
mesenchyme.
Image B is from Review: Little, M., Georgas, K., Pennisi, D., and Wilkinson, L. (2010). Kidney development: two tales of
tubulogenesis. Current topics in developmental biology 90, 193-229. Figure used with permission.
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1.4 Functions of progenitor markers FOXD1, SIX2 and CITED1 in renal progenitors
Expression of FOXD1, SIX2 and CITED1 demarcates stromal or nephron progenitors,
respectively. It is important to understand the roles of each marker in renal progenitors
during kidney development.
Foxd1, a transcription factor, is expressed in the cortical stromal mesenchyme (Hatini et
al., 1996). FOXD1 expressing cells have been shown to be the multipotent self-renewing
stromal progenitors in mouse kidneys (Kobayashi et al., 2014). Foxd1 knockout mice died
immediately after birth with a phenotype of renal agenesis, demonstrating an essential role
of the FOXD1+ stromal mesenchyme in nephrogenesis (Hatini et al., 1996). Through
paracrine signaling, Foxd1 regulates the epithelial differentiation of the nephron
mesenchyme and the growth and branching of the ureteric bud (Zhang et al., 2003).
In the CM, Six2, a homeobox transcription factor, is required for the maintenance of selfrenewal and multipotency of the nephron progenitor in an autonomous manner (Kobayashi
et al., 2008). SIX2 is expressed in both uninduced CM and induced CM, but the expression
of SIX2 decreases in the RV (Mugford et al., 2009). Six2 deletion mice died shortly after
birth and showed renal hypogenesis (Self et al., 2006). Six2 deletion caused the depletion of
the nephron progenitors and the ectopic differentiation of the nephron progenitors to
epithelial cells (Self et al., 2006). Six2 activates its own expression autonomously (Brodbeck
et al., 2004). To maintain the nephron progenitor, SIX2 is required for the expression of
OSR1, which interacts with SIX2 through the TCF/LEF complex (Xu et al., 2014a). SIX2 and
β-CATENIN compete to interact with the TCF/LEF complex in the nephron progenitors.
However, SIX2 maintains the self-renewal capacity, whereas β-CATENIN promotes
differentiation (Park et al., 2012).
CITED1, Cbp/p300-interacting transactivator with Glu/Asp-rich C-terminal domain 1, is a
non-DNA binding transcpitional regulator. CITED1 is exclusively expressed in the nephron
progenitor in the uninduced CM, and its expression decreases as the progenitor starts to
9

differentiate (Boyle et al., 2008). However, Cited1 deletion does not affect kidney
development, suggesting that it is not required for nephrogenesis (Boyle et al., 2007).

1.5 Signaling and interactions between kidney progenitor compartments
There are networks of intensive signaling and crosstalk between stromal progenitors,
nephron progenitors and ureteric buds to orchestrate the complex molecular interactions
and morphogenesis in kidneys (Fig. 1.3 B).
The metanephric mesenchyme expresses and secretes the growth factor GDNF which
then binds to the GDNF receptor C-RET expressed in the cells of the ureteric buds (Patel
and Dressler, 2013; Schuchardt et al., 1994). GDNF expression in the MM is controlled by
transcription factors Eya1, Pax2, and Six1 and Six2 (Reidy and Rosenblum, 2009). The
GDNF-C-RET signaling induces the outgrowth and branching of the ureteric bud through the
PI-3K/AKT and ERK pathways (Tang et al., 2002). GDNF-C-RET signaling also increases
the cell migration ability of ureteric buds to promote ureteric bud invasion into the
metanephric mesenchyme (Tang et al., 1998).
Reciprocally, the ureteric bud sends signals to the nephron progenitors to regulate cell
survival, proliferation and differentiation (Mori et al., 2003). To maintain nephron progenitor
survival, FGF signaling is critical. Specifically, FGF9 secreted from the ureteric buds and
FGF20 expressed in the CM are necessary and sufficient for nephron progenitors to
proliferate, survive and maintain stemness (Barak et al., 2012). WNT9B derived from the
ureteric buds is also required for the self-renewal and proliferation of nephron progenitors
via canonical β-CATENIN signaling (Karner et al., 2011). Also, WNT9B/β-CATENIN induces
early differentiation the CITED1+ nephron progenitors (Carroll et al., 2005). SIX2 and
WNT9B/β-CATENIN coordinate the balance between the maintenance of stemness and
differentiation (Karner et al., 2011). In the presence of WNT9B/β-CATENIN signaling,
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nephron progenitors with high levels of SIX2 favor maintenance of self-renewal and
proliferation, whereas progenitors with low expression of SIX2 are stimulated to differentiate
by WNT9B/β-CATENIN (Karner et al., 2011). WNT9B activates WNT4 in differentiating cells
to form renal vesicles (Carroll et al., 2005). Although activation of β-CATENIN induces
differentiation, levels of this protein must be reduced and fine-tuned in order for cells to
further differentiate and epithelialize (Park et al., 2007). Moreover, in vivo genetic studies
have shown that Notch signaling can substitute for WNT signaling and induce the
mesenchyme to epithelia transition of nephron progenitor (Boyle et al., 2011).
Stromal mesenchyme is also critical in regulating functions of nephron progenitors. The
stromal progenitor is required for renal morphogenesis (Hum et al., 2014). Deletion of
Foxd1, a marker for stromal progenitors, leads to failed differentiation of the nephron
progenitors through DCN (Small leucine rich proteoglycan decorin)–BMP/SMAD signaling
from stromal progenitors (Fetting et al., 2014). BMP-SMAD signaling primes the
CITED1+SIX2+ uninduced nephron progenitors to be susceptible to induction of
differentiation (Brown et al., 2013). FAT-HIPPO signaling from stromal mesenchyme
cooperates with WNT9B to control the differentiation of nephron progenitors (Das et al.,
2013).
Both the stromal mesenchyme and the ureteric buds send signals to nephron
progenitors and coordinate the control of nephron progenitor maintenance and
differentiation. However, not much is known about whether the stromal progenitors are
regulated by the nephron progenitors or the ureteric buds and how they are regulated.

1.6 Pre-MM: Induction of metanephric mesenchyme
The metanephric mesenchyme (MM) is derived from the intermediate mesenchyme.
There are many key transcription factors that interact to generate and define the MM. These
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transcription factors, such as Osr1, Eya1, Hox11, Six1 and Pax2, are expressed in the
intermediate mesoderm and the MM, and are critical for the specification of the MM. Genetic
studies have shown that loss of function of these transcription factors causes hypoplasia or
kidney agenesis (Patel and Dressler, 2013).
OSR1 is expressed in the intermediate mesenchyme cells from which both metanephric
stromal progenitors and nephron progenitors arise (Mugford et al., 2008b). OSR1 is
required for the induction of metanephric mesenchyme from the intermediate mesenchyme
(Wang et al., 2005). In the metanephric mesenchyme, OSR1 expression is restricted to the
CM (SIX2+) and it works synergistically with SIX2 to maintain nephron progenitors (Mugford
et al., 2008b) (Xu et al., 2014a).
EYA1 is also expressed in the intermediate mesenchyme. EYA1+ cells in the
intermediate mesenchyme give rise to the nephron forming cells. Deletion of Eya1 results in
loss of SIX2 and premature epithelialization of the nephron progenitors, indicating that Eya1
is important in regulating nephron progenitor self-renewal (Xu et al., 2014b). Eya1-/- mice do
not have the outgrowth of the ureteric bud and the specification of the metanephric
mesenchyme, which is likely mediated through SIX1 and PAX2 (Xu et al., 1999) (Sajithlal et
al., 2005).
Hox11 is a paralogous set of genes, Hoxa11, Hoxc11 and Hoxd11, with redundant
functions in regulating kidney development. HOXD11 has been shown to activate SIX2 in
the intermediate mesenchyme and commit the intermediate mesenchyme to the MM
(Mugford et al., 2008a). The triple compound mutant Hoxa11-/-Hoxc11-/-Hoxd11-/- results in a
failure in the induction of MM and the outgrowth of the ureteric bud (Wellik et al., 2002).
HOX11 interacts with PAX2 and EYA1 and the formed HOX-PAX-EYA complex is essential
to activate Six2 to maintain the nephron progenitor population (Gong et al., 2007).
PAX2 is expressed in the mesenchymal and ductal components of the urogenital system
(Torres et al., 1995). Pax2 and its related Pax gene family member, Pax8, are required and
12

sufficient for the specification of nephric lineage from the intermediate mesenchyme
(Bouchard et al., 2002). Pax2 activates Wnt4 to induce the nephron progenitor to
differentiate (Torban et al., 2006). Pax2 deletion mice resulted in failure to develop kidneys,
ureters and genital tracts (Torres et al., 1995).

1.7 Post-MM: Epithelial differentiation of nephron progenitor
In the MM, after the induction of differentiation, the nephron progenitor undergoes MET
and forms the renal vesicles, where as Wnt4, Pax8, Lef1, Lhx1 and Fgf8 are expressed to
promote epithelial differentiation (Mugford et al., 2009) (Little and McMahon, 2012). The
renal vesicle is comprised of primitive epithelium with a basement membrane and a lumen,
located proximal to the ureteric bud (Patel and Dressler, 2013). During morphogenesis, the
renal vesicle is followed by the formation of the comma-shaped body, S-shaped body, and
fully differentiated nephron (Patel and Dressler, 2013). Gene expression analysis identified a
restricted expression pattern of marker genes in the renal vesicle, which correlates to the
specification of glomerular, proximal and distal segments (Little and McMahon, 2012). Along
the proximal-distal patterning, CADHERINs are differentially expressed, reflecting the
regionalization of segmentation (Little and McMahon, 2012). CADHERIN-6 is a marker for
the proximal compartment in the comma-shaped body and S-shaped body (Cho et al.,
1998). E-CADHERIN is expressed in more maturely differentiated epithelium such as the
proximal tubule and distal tubule (Shimazui et al., 2000). A study of the molecular
mechanism of nephron patterning has shown Notch2 null mutants lack the formation of the
proximal segments, suggesting that NOTCH signaling is required for nephron segmentation
(Cheng et al., 2007).
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1.8 Molecular profiling of Wilms tumors showed a similar profile to the early stage of
kidney development
Wilms tumor not only recapitulates the fetal kidney histologically, but it also molecularly
mimics the gene expression pattern of fetal kidney. A comparison of gene expression
analysis between Wilms tumors and fetal kidneys at early and late stage of development
revealed that the gene expression profile of Wilms tumor was similar to that of the
committed metanephric mesenchyme in the transition of mesenchyme to epithelia (Li et al.,
2002). The overexpressed genes shared by both Wilms tumor and the metanephric
mesenchyme included Pax2, Eya1, HBF2, Hoxa11, Six1, Meox1 and Sall2, which play an
important role on the survival, proliferation and function of the mesenchyme cells (Li et al.,
2002). Further analysis of transcription profile of specific cellular components in Wilms
tumors, e.g. the blastemal, epithelial and stromal, demonstrated that all these components
expressed genes that are highly expressed in metanephric mesenchyme at the earliest
stage of renal development (Maschietto et al., 2008). Tumors also expressed genes
expressed at a late stage of differentiation. However, tumor blastema had the least in
common with the expression profile at a later stage of differentiation, while the tumor
epithelial and stromal elements showed higher commonality with it (Maschietto et al., 2008).
These molecular profiling results indicate that Wilms tumor arises from cells arrested at an
early metanephric mesenchymal stage during kidney development.

1.9 Wilms tumor genetics: WT1, β-CATENIN, WTX, and IGF2
Mutations of a few genes have been identified in Wilms tumors, such as Wilms Tumor
Gene 1 (WT1), β-CATENIN (CTNNB1), Wilms Tumor gene on the X chromosome (WTX)
(Ruteshouser et al., 2008), IGF2 (Ogawa et al., 1993), DROSHA, DICER1 (Wu et al., 2013)
and TP53 (Bardeesy et al., 1994; Huff, 2007).
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WT1 is found mutated in 20% of tumors. The mutations included deletion, truncation or
missense mutations, which resulted in the loss of functional WT1 (Ruteshouser et al., 2008).
WT1 mutations are associated with mixed triphasic histology in Wilms tumors (Gadd et al.,
2012). WT1 is a transcription factor with four Kruppel type zinc finger domains and regulates
the expression of genes involved in cell differentiation, survival and proliferation (Mrowka
and Schedl, 2000). One of its isoforms also regulates mRNA processing (Hohenstein and
Hastie, 2006). Wt1 knock-out mice lacked the development of kidneys and died at midgestation due to defects in the development of cardiovasculature (Kreidberg et al., 1993).
70% of Wilms tumors exhibited loss of imprinting of IGF2, resulting in biallelic expression
of IGF2 (Steenman et al., 1994). The H19-Imprinting Control Region (ICR) region on the
maternal allele transcriptionally represses the expression of IGF2 on the same allele.
Normally IGF2 is expressed from the paternal allele but not the maternal one. However,
deletion of H19-ICR region on the maternal allele results in biallelic Igf2 expression
(Leighton et al., 1995). IGF2 is a fetal mitogen that promotes proliferation of mesenchymal
cells in kidney development.

β-CATENIN activation mutations occur in 15% of Wilms tumors and are frequently found
associated with WT1 mutations (Maiti et al., 2000). Studies have found a sequential
occurrence of genetic alterations during the progression from nephrogenic rest to tumor
(Fukuzawa et al., 2007). In the same individual, the nephrogenic rests carried only WT1
mutation, but the tumor had the same WT1 mutation and an additional β-catenin mutation
(Fukuzawa et al., 2007). This result suggests that a WT1 mutation in nephrogenic rests is
essential but not sufficient for cell transformation, and when a second mutation such as βCATENIN stabilization occurs, the nephrogenic rest becomes tumorigenic (Fukuzawa et al.,
2007).
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WTX, a gene on the X chromosome, is found mutated in 20% of Wilms tumors
(Ruteshouser et al., 2008). WTX has been shown to negatively regulate WNT/β-CATENIN
signaling (Major et al., 2007). Mutant mice with germ-line knock-out of Wtx died after birth
and had malformation in the mesenchyme derived tissues (Moisan et al., 2011). Wtx
deletion in the mesenchyme progenitors resulted in changed fate of the lineage restricted
cells and delayed differentiation due to increased WNT/β-CATENIN signaling (Moisan et al.,
2011).
DICER1 syndrome patients who have germ-line DICER null mutations are predisposed
to Wilms tumors. Very recently, genes involved in the micro RNA biogenesis pathway were
found to be associated with 15% Wilms tumors (Torrezan et al., 2014). These genes include
DROSHA (12%) (Torrezan et al., 2014), DICER1 (2.6%) (Wu et al., 2013) and some other
micro RNA processing genes, suggesting a role of micro RNA biogenesis in Wilms tumor
development (Torrezan et al., 2014).

1.10

Wilms tumor mouse models

Three different genetic mouse models of Wilms tumors have been generated so far. Our
lab has generated the first one by ablating Wt1 somatically and mosaically in the
background of bi-allelic Igf2 expression (Hu et al., 2010). In this model, a tamoxifen
inducible Cre-ERTM was used to ablate Wt1 mosaically and somatically at E11.5, an early
stage of kidney development (UbCre-Wt1-Igf2). The Wt1 was ablated by CRE in a nonspecific manner in kidney cells. This mouse model of Wilms tumor had typical triphasic
histology, mimicking the triphasic histology of human Wilms tumors. Developmentally, Wt1
ablation only blocked mesenchyme differentiation (Hu et al., 2010). The tumors with Wt1
ablation and Igf2 upregulation had increased ERK signaling, corresponding to a subset of
human WTs with elevated ERK1/2 phosphorylation (Hu et al., 2010).
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A second genetic mouse model of Wilms tumor had stabilized β-CATENIN with or
without the activation of K-RAS in kidney epithelial cells (Clark et al., 2011). This study
applied a metanephric mesenchyme specific tamoxifen inducible Cre, Cited1CreERT2, and
activated the CRE postnatally to stabilize β-CATENIN by deleting exon 3 of Ctnnb1. In
addition to targeting the mesenchyme, they also used a proximal tubule specific Cre
transgene γGT-Cre to activate β-catenin and K-Ras. With both methods, mutant mice
developed primitive epithelial Wilms tumors. Moreover, the activation of both β-catenin and
K-Ras synergistically caused metastasis of Wilms tumors to the lungs. Molecularly, the
mouse primary Wilms tumors showed increased ERK and PI3K/AKT signaling (Clark et al.,
2011).
Very recently, the overexpression of Lin28 with Wt1-Cre induction in the intermediate
mesenchyme derivatives led to the development of Wilms tumors (Urbach et al., 2014).
Lin28 is an RNA-binding protein and is important in the maintenance of stem cell
proliferation and self-renewal (Urbach et al., 2014). The tumors with Lin28 overexpression
displayed a phenotype of being arrested at an early differentiation stage in the cap
mesenchyme. It has been shown that in the mouse Wilms tumors Lin28 acted through the
microRNA Let7 signal transduction pathway (Urbach et al., 2014). However, Lin28
overexpression in stromal progenitors (Foxd1-Cre), nephron progenitors (Six2-Cre) or
ureteric buds (Chd16-Cre), did not induce Wilms tumors (Urbach et al., 2014). Microarray
and IHC analysis showed that Lin28B but not Lin28A was expressed in human Wilms
tumors and the expression levels of Lin 28B was significantly associated with increased
severity of tumor progression (Urbach et al., 2014).
These mouse Wilms tumor models provided useful tools to study the mechanisms of
Wilms tumor development in vivo; however, in these tumor models the genetic alterations
were introduced randomly into developing kidney cells, or post-natal kidney cells, or pre-
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metanephric mesenchme cells. It is still not clear what types of cells in the metanephric
kidney, or at what differentiation state during renal development, initiate the development of
Wilms tumors. These are the questions that our study specifically addressed.

1.11

Cell Origins of Wilms tumors

A study of global gene expression array with a large panel of human Wilms tumors has
identified 5 subsets of Wilms tumors (Table 1) (Gadd et al., 2012). These subsets are
different in gene expression profiles, histological features, and clinical outcomes (Gadd et
al., 2012). For example, Subset 1 is characterized by differentiated epithelial histology and a
gene expression signature corresponding to terminal epithelial differentiation. Clinically,
patients within this subset had no tumor relapses. On the other hand, Subsets 2-4 are
characterized by triphasic histology with undifferentiated blastemal cells mixed with epithelial
and stromal cells, and these tumors had gene expression signatures corresponding to early
stage of the mesonephric mesenchyme and renal interstitium. Moreover, 10-50% of these
patients had tumor recurrences. These data suggested that the different Wilms tumor
subsets arise from cells at different stages of mesenchyme differentiation (Gadd et al.,
2012). Therefore, we hypothesized that the differentiation status of the initially mutated cell
impacts the formation of different types of Wilms tumors. Addressing this hypothesis will
help us to understand how the different types of Wilms tumors occur and potentially help us
to develop improved therapy accordingly.
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Table 1. Identification of human WT subsets based on
gene expression array
Relapse

Histology

Signature genes

Subset 1
(S1)

0/11

Epithelial
differentiated

After MET and in terminally
differentiated epithelium
e.g. NOTCH signaling, HOXA11,
MEIS2

Subset 2
(S2)

2/23

Triphasic,
muscle
differentiation
elements

Very early mesonephric mesenchyme
and renal interstitium
e.g. NFAT and TGFB signaling,
TWIST1, DLK1, WIF1, MYH3, TTN,
ACTA1

Subset 3
(S3)

7/21

Similar to S2,
less muscle
differentiation

NFAT, TGFB and RAS signaling

Subset 4
(S4)

6/11

Similar to S2

Similar to S2

Subset 5
(S5)

50/158

Triphasic, mostly
blastema
predominant

Early metanephric mesenchyme
e.g. SIX1, PAX2, EYA1, HOXA11
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Previously, our lab generated a mouse model of Wilms tumor by using a ubiquitous Cre
to somatically and mosaically ablate Wt1 at E11.5 in the background of Igf2 over-expression
(Hu et al., 2010). In this model, Wt1 ablation is essential for the development of mouse
Wilms tumors. However, it is unclear what cell types were targeted with Wt1 ablation and
consequently gave rise to tumors. At E11.5, WT1 is expressed in the metanephric
mesenchyme mainly composed of stromal progenitors and nephron progenitors. In this
mouse model, when Wt1 is ablated randomly with the ubiquitous Cre, the stromal
progenitors or the nephron progenitors could have been targeted and serve as promising
candidates for the tumor initiating cells. To find out the cell origins of Wilms tumors, we
applied the same approach of generating the mouse tumor model by using Cre-Loxp
system, but we used progenitor cell-type specific tamoxifen-inducible Cre to introduce
genetic mutations into specific cellular compartment (stromal progenitor or nephron
progenitor) in the metanephric mesenchyme.

1.12

Targeting kidney progenitors with the cell-type specific Cre

The abilities of self-renewal and multipotency in progenitor cells make them a promising
candidate as tumor initiation cells. To determine whether the kidney progenitors are the
primary targets for cell transformation, progenitor specific tamoxifen-inducible CreER alleles
were used. Foxd1GCE was used to target the stromal progenitor and Six2GCE or Cited1Cre was
used to target the nephron progenitor. Since Wt1 loss-of-function and β-catenin activating
mutations are often found in Wilms tumors, it is clinically and molecularly relevant to
introduce these genetic mutations to the mouse and generate mouse Wilms tumors. The
Cre-LoxP system was applied to induce Wt1 ablation or β-CATENIN stabilization in kidney
stromal progenitor or nephron progenitor.
Foxd1GCE (stomal progenitor specific) and Six2GCE (nephron progenitor specific) knock-in
alleles replace endogenous exon 1 at the initiation codon of Foxd1 or Six2, respectively,
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with a gene cassette of GFP and tamoxifen inducible Cre (GCE) (Fig. 1.4 A). The
Foxd1GCE/GCE and Six2GCE/GCE mutant homozygote mice die soon after birth, but the
heterozygotes are viable and phenotypically normal (Hatini et al., 1996) (Self et al., 2006).
The Cited1Cre is a BAC transgene in which GFP-CRE expression is under the transcriptional
control of 190 kb genomic sequence 5’ of the Cited1 gene (Fig. 1.4 A) (Boyle et al., 2008).
All three Cre lines have been shown to express the CRE recombinase where endogenous
FOXD1, SIX2 or CITED1 proteins are normally expressed in the fetal kidney. Therefore, with
the inducible CRE, we could introduce Wt1 ablation or β-CATENIN stabilization in a
progenitor cell type-specific manner to study cell origins of Wilms tumors.
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A

Progenitor-specific Cre constructs

Foxd1GCEor Six2GCE knock-in allele
Foxd1 or Six2 promoter
eGFPCreERT2-SV40pA

PGK-neo-bpA

Exon 1

Cited1-Cre BAC transgene
BAC Cited1 locus
CreERT2-IRESeGFP

TetR

DNA binding domain

B
Wt1

Dysfunctional Wt1

C
β-catenin

Cre
Stabilized β-Catenin
Figure 1.4 Diagram of progenitor-specific Cre alleles and Wt1 and βcatenin flox alleles.
(A)The construct of Foxd1GCEor Six2GCE knock-in alleles. (B) Constructs of Wt1fl
and Wt1∆ alleles. (C)The construct of β-catenine3fl and β-catenine3∆ alleles.
Image B is from Gao, F., Maiti, S., Alam, N., Zhang, Z., Deng, J.M., Behringer, R.R., Lecureuil, C., Guillou, F., and Huff,
V. (2006). The Wilms tumor gene, Wt1, is required for Sox9 expression and maintenance of tubular architecture in the
developing testis. Proceedings of the National Academy of Sciences of the United States of America 103, 1198711992. (Copyright (2006) National Academy of Sciences, U.S.A.) Image C is from Mucenski, M.L., Nation, J.M.,
Thitoff, A.R., Besnard, V., Xu, Y., Wert, S.E., Harada, N., Taketo, M.M., Stahlman, M.T., and Whitsett, J.A. (2005).
Beta-catenin regulates differentiation of respiratory epithelial cells in vivo. American journal of physiology Lung cellular
and molecular physiology 289, L971-979. Figures used with permission.
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1.13

Wt1 in kidney development and Wilms tumor

1.13.1 Wt1 is a transcription factor
Wt1 is a transcription factor and RNA binding protein. The human WT1 gene is about 50
kb in size, encoding a 3 kb mRNA with 10 exons (Call et al., 1990). The WT1 protein has
four Kruppel-type zinc fingers at the carboxyl terminus, which are involved in DNA binding
(Call et al., 1990). Exons 8-9 encode the second and third DNA binding domains which are
critical for Wt1 functions. To disrupt Wt1 function, loxP sites were inserted flanking exons 89 and, in the presence of CRE recombinase, the in-frame deletion of Exons 8-9 results in
truncated, inactive Wt1 (Fig. 1.4 B) (Gao et al., 2006).
WT1 has many isoforms due to alternative translational start sites, alternative splicing
and RNA editing (reviewed in (Hohenstein and Hastie, 2006)). Alternative splicing results in
the inclusion or exclusion of exon5 and of 3 amino acids (lysine-threonine-serine, KTS) at
the 3 prime end of exon 9 (Hohenstein and Hastie, 2006). The KTS- isoform binds to DNA
with a high affinity and functions as a transcription factor (Hohenstein and Hastie, 2006).
The KTS+ Wt1 isoform has a low DNA binding affinity, but interacts with RNA preferentially
(Hohenstein and Hastie, 2006). These various isoforms remain in relative proportion in fetal
kidney (Hohenstein and Hastie, 2006).
WT1 can transcriptionally activate or repress downstream target genes, depending on
the cellular context and interacting proteins. Some of the downstream targets include Egfr
(Englert et al., 1995), Igf2 (Drummond et al., 1992), Pax2 (Ryan et al., 1995), Wnt4 (Sim et
al., 2002) and Amphiregulin (Lee et al., 1999), which are all important in kidney
development. A systematic genome-wide study was carried out to identify Wt1 targets
controlling cell function and differentiation of nephron progenitors (Hartwig et al., 2010). This
study analyzed embryonic kidneys at E18.5 and used the approaches of chromatin
immunoprecipitation and mouse promoter microarray. The defined targets associated with
renal agenesis are WNT inhibitor Cxxc5, MAP kinase signaling effector Erk1, epigenetic
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regulators such as Rest and Jmdj3, and proteins involved in TGFβ/BMP signaling (Hartwig
et al., 2010).

1.13.2 WT1 is a tumor suppressor in Wilms tumors
WT1 is defined as a tumor suppressor in Wilms tumors given that loss of function of
WT1 predisposes patients to Wilms tumor development. Predisposition to Wilms tumor is
observed in four congenital syndromes, WAGR, Denys-Drash, Beckwith-Wiedemann and
Frasier syndromes, most of which have genitourinary defects (Mrowka and Schedl, 2000),
and all of which involve alterations of chromosome 11p13-15. Germ-line WT1 mutations are
associated with bilateral tumors and an early age at diagnosis, but there is no difference in
overall survival between patients with and without WT1 mutations (Discenza and Pelletier,
2004).
However, many Wilms tumors with wild type WT1 overexpress WT1. High expression of
wild type WT1 in Wilms tumor result in the arrest of undifferentiated mesenchymal cells at
early differentiation and suggests that factors controlling the WT1 expression are preserved
in tumors. WT1 is also overexpressed in most acute myelogenous leukemia, acute
lymphoblastic leukemia, chronic myelogenous leukemia (CML), and myelodysplastic
syndrome (MDS) (Rosenfeld et al., 2003). In breast cancer, WT1 has been implicated as an
oncogene since its high expression is associated with poor prognosis (Miyoshi et al., 2002).
WT1 plays different roles in tumor development of different kinds of cancers.

1.13.3 Wt1 is required for nephrogenesis
WT1 plays an essential role in kidney development. Wt1 has been shown to have
different functions at different stages of kidney development (Elizabeth, 2014). In the
developing kidney, Wt1 is weakly expressed in the intermediate mesoderm and metanephric
mesenchyme (Armstrong et al., 1993). The expression of WT1 increases in the proximal
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segment of the comma-shaped body and S-shaped body, the precursor of glomerular
podocytes (Grubb et al., 1994). Then its expression is restricted to the podocytes of
nephrons (Grubb et al., 1994).
Wt1 is required for cell survival in the intermediate mesoderm, as Wt1 knock-out in mice
led to cell apoptosis in the intermediate mesoderm and the metanephric mesenchyme,
resulting in disruption in urogenital development (Kreidberg et al., 1993). In the metanephric
mesenchyme, Wt1 is essential for the mesenchyme to epithelial transition (Hu et al., 2010).
Conditional ablation of Wt1 in the metanephric mesenchyme at E11.5 resulted in lack of
condensation of the mesenchyme around the ureteric bud tips, expansion of the
mesenchymal region, and blocked mesenchyme to epithelia transition (Hu et al., 2010). The
expanded mesenchyme caused by Wt1 deletion arrested before the MET makes the
mesenchymal cells at the pre-MET stage a very likely candidate for tumor development
(Elizabeth, 2014). In the metanephric mesenchyme, Wt1 transcriptionally activates the
expression of Wnt4 and thus stimulates epithelial differentiation (Sim et al., 2002). In the
mature nephron, Wt1 is highly expressed in the podocytes, and reduced expression of Wt1
causes the accumulation of matrix in the basement membrane, thus leading to crescentic
glomerulonephritis or mesangial sclerosis (Guo et al., 2002).
Wt1 is expressed in the metanephric mesenchyme including stromal progenitors and
nephron progenitors and it regulates cell apoptosis, survival and MET during kidney
development. However, its specific function in each renal progenitor cell type remains
unclear. Using the progenitor-specific Cre to ablate Wt1 in the mouse, we can dissect out its
in vivo effects on nephrogenesis in either stromal progenitor or nephron progenitor and this
knowledge would help us understand the mechanisms by which Wt1 mutations predispose
to the development of Wilms tumors.
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1.14

WNT/β-CATENIN in kidney development and Wilms tumor

1.14.1 WNT/β-CATENIN signaling
The WNT/β-CATENIN signal transduction pathway is critical in embryogenesis and is
often associated with cancer development. WNT proteins are a family of secreted
glycolipoproteins that interact with the receptors of the FRIZZLED proteins and the LDL
receptor-related proteins 5 and 6 LRP5/6) (MacDonald et al., 2009). The WNT ligands act
through β-CATENIN dependent (canonical) pathways or β-CATENIN independent (noncanonical) pathways. The non-canonical pathways include the Planar Cell Polarity (PCP)
pathway and the WNT/Ca2+ pathway (Komiya and Habas, 2008).
In the canonical pathway, β-CATENIN is the mediator of WNT ligand induced signaling.
Without WNTs, β-CATENIN is susceptible to protein degradation by the APC complex
composed of the scaffolding protein AXIN, the tumor suppressor adenomatous polyposis
coli protein (APC), casein kinase 1 (CK1), and glycogen synthase kinase 3 (GSK3)
(reviewed in (MacDonald et al., 2009)). Initially β-CATENIN binds to AXIN, then β-CATENIN
is phosphorylated by CK1 at Ser45 in β-catenin exon 3, and is subsequently phosphorylated
by GSK3 at Ser33, Ser37 and Ser41 (reviewed in (Voronkov and Krauss, 2013)). CK1 and
GSK3 also phosphorylate APC, and phosphorylated APC has a higher affinity for βCATENIN, resulting in the transfer of β-CATENIN to APC from AXIN. The N-terminal
phosphorylated β-CATENIN in the APC complex is exposed to ubiquitinase β-TrCP and
subjected to proteasomal degradation (reviewed in (Voronkov and Krauss, 2013)). WNT
ligands, such as WNT9 and WNT4, bind to the receptor complex LRP5/6-Frizzled and the
complex recruits the scaffold proteins DISHEVELLED and AXIN, thus inhibiting AXINmediated β-CATENIN phosphorylation and the subsequent β-CATENIN degradation
(reviewed in (Voronkov and Krauss, 2013)). Thus, β-CATENIN is stabilized and accumulates
in the cytoplasm. The accumulated β-CATENIN is translocated to the nucleus where it
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interacts with transcription repressor complex the TCF/LEF, activating the expression of
downstream targets (reviewed in (MacDonald et al., 2009)). With the genetic in-frame
deletion of exon3 (Fig. 1.4 C), β-catenin is not susceptible to phosphorylation and is
therefore stabilized, thus activating downstream oncogenic events (Harada et al., 1999).

1.14.2 WNT/β-CATENIN in renal progenitors
β-CATENIN signaling is critical in nephron progenitors. Deletion of β-catenin in nephron
progenitors using the Six2-Cre transgene led to failed formation of renal vesicles and no
expression of induction markers in renal vesicles such as Fgf8, Wnt4, Pax8 and Lhx1 (Park
et al., 2007). β-CATENIN activation stimulated nephron progenitors to go through MET and
ectopically express markers of renal vesicles (Park et al., 2007). Thus, β-CATENIN is
necessary and sufficient to initiate MET induction in nephron progenitors. However, a
constant high level of β-CATENIN activity in nephron progenitors did not result in complete
epithelial differentiation such as the formation of E-CADHERIN expressing epithelium (Park
et al., 2007). Therefore, transient activation of β-catenin is required to induce differentiation
of nephron progenitor to renal vesicle stage, but to further epithelialize, β-CATENIN activity
has to be reduced and fine-tuned (Park et al., 2007). β-CATENIN is activated by WNT9B
from the ureteric bud and WNT9B activates WNT4 in the induced nephron progenitor to
increase β-CATENIN signaling (Karner et al., 2011). β-CATENIN acts through the Tcf/Lef
transcriptional program to maintain the survival, proliferation and early differentiation of
nephron progenitors (Schmidt-Ott and Barasch, 2008). To promote the differentiation of the
nephron progenitor, nuclear β-CATENIN is increased by stromal cells in the niche through
FAT4-HIPPO signaling (Das et al., 2013). SIX2 counteracts β-CATENIN initiated
differentiation signals via TCF/LEF complex to maintain nephron progenitor self-renewal
(Park et al., 2012).
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For the stromal progenitors, β-CATENIN has been shown to be expressed in the cell
membrane (Das et al., 2013) and is likely involved in cell-cell adhesion junctions.
Conditional deletion of β-catenin using Foxd1-Cre did not show any abnormality in nephron
induction or ureteric bud branching, however, the mutants had slightly thicker cortices and
failed development of the medulla (Yu et al., 2009). Wnt2b is expressed in the stromal
mesenchyme, but Wnt2/Wnt2b double knock out mice did not show abnormal phenotype in
the kidney (Goss et al., 2009). These results suggested that WNT/β-CATENIN did not seem
to be essential for the functions of stromal progenitors, but the specific roles of WNT/βCATENIN signaling in the stromal progenitors still remains to be investigated.

1.14.3 WNT/β-CATENIN in Wilms tumors
High activity of β-CATENIN is associated with numerous cancers. β-catenin stabilization
mutations or nuclear accumulation of β-CATENIN is often found in Wilms tumors with
stromal histology and ectopic mesenchymal elements such as myogenesis or
chondrogenesis (Fukuzawa et al., 2009). Wilms tumors with β-catenin mutations showed
high expressions of β-catenin targets PITX2 and APCDD1, Wnt/β-catenin extracellular
inhibitors, muscle-related genes and oncogenes in retinoic acid and RAS pathways (Zirn et
al., 2006). In Wilms tumors, β-CATENIN stabilization mutations are frequently associated
with WT1 loss of function mutations (Maiti et al., 2000). Another genetic study of Wilms
tumors also found β-CATENIN stabilization mutations were detected only in WT1 mutated
Wilms tumors (Li et al., 2004). These tumors also expressed high level of genes such as βCATENIN/TCF targets, WNT inhibitors, myogenic differentiation factors and TGF-β signaling
(Li et al., 2004).
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Summary
Wilms Tumor is thought to arise from the undifferentiated metanephric mesenchyme,
and the observation of distinctive subsets of tumors suggests that each subset arises from
cells at different stages of differentiation (Gadd et al., 2012). In this thesis, by using mouse
genetic models, we applied progenitor-specific CreER to somatically and mosaically introduce
Wt1 ablation in the context of Igf2 biallelic expression or β-catenin activation into stromal
progenitors and nephron progenitors. We investigated whether Wilms tumors could arise
from fetal kidney cells at distinct differentiation statuses and whether specific kidney
progenitor populations could produce different types of Wilms tumors with respect to tumor
initiation, growth and pathology. We also studied the impact of different types of gene
mutations on the development of Wilms tumors. Moreover, with the same approach, we
studied the effects of Wt1 ablation on kidney development to understand how Wt1 ablation
predisposes to malignant transformation. These results could provide insights into the cell
origins of Wilms tumor and the mechanisms of tumor initiation and development and also
help us to understand the functions of Wt1 in stromal progenitors and nephron progenitors.
Potentially the mouse model studies will help us to develop improved therapies that target
different types of tumors specifically and trigger the most effective responses according to
the tumor cell origins or tumor types.
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Chapter 2: Materials and Methods
2.1 Mice
The mice were housed and handled according to the guidelines of The University of
Texas MD Anderson Cancer Center Institutional and Animal Care and Use Committee. All of
the mice were maintained on a C57BL/6J x 129/SvEv mixed genetic background.
Littermates of the mutant mice were used as controls. The mice were genotyped via
standard PCR analysis of genomic DNA isolated from the tails as described previously (Gao
et al., 2006; Harada et al., 1999; Hayashi and McMahon, 2002; Leighton et al., 1995).
Foxd1GCE/+, Six2GCE/+, Cited1Cre, R26tdTomato/tdTomato, Wt1+/-, Wt1fl/fl, β-catenine3fl/e3fl, and H19/-

mice described previously (Humphreys et al., 2010) (Kobayashi et al., 2008) (Boyle et al.,

2008) (Kreidberg et al., 1993) (Gao et al., 2006) (Harada et al., 1999) (Leighton et al., 1995)
were used in this study. We bred the Foxd1GCE/+ or Six2GCE/+ or Cited1Cre with Wt1+/- mice to
generate Foxd1GCE/+; Wt1+/- or Six2GCE/+; Wt1+/- or Cited1Cre; Wt1+/- male mice. Wt1fl/fl mice
were bred with β-catenine3fl/e3fl or H19-/- or R26tdTomato/tdTomato or R26 βgal/βgal mice for a few
generations to generate females that were Wt1fl/fl; β-catenine3fl/e3fl or Wt1fl/fl; H19-/- or Wt1fl/fl;
R26tdTomato/tdTomato or Wt1fl/fl; R26 βgal/βgal.

2.1.1 β-gal reporter analysis of Foxd1GCE and Six2GCE mice
Tamoxifen was dissolved in corn oil and injected at E11.5 or E14.5 intraperitoneally into
pregnant mice (R26βgal/ βgal) mated with Foxd1GCE/+ or Six2GCE/+ male mice. Kidneys (Cre+;
R26βgal/+) were analyzed at E14.5 and E19.5 with littermates (R26βgal/+) as controls. When
tamoxifen was injected at E11.5, kidney sections at E14.5 showed that both Foxd1GCE and
Six2GCE Cre alleles were effective to induce recombination (Fig. 3.2, A and C). However,
when tamoxifen injection time was at E14.5, kidney sections at E19.5 showed that only
Six2GCE but not Foxd1GCE was efficient in inducing recombination (Fig. 3.2, B and D). This
30

result provided us information on the conditions of tamoxifen injection time for the mouse
tumor cohort generation. To target progenitor cells effectively, tamoxifen was administered
at E11.5 for Foxd1GCE cohort generation, but at E11.5 or E14.5 for Six2GCE cohort
generation.

2.1.2 tdTOMATO reporter analysis of Foxd1GCE, Six2GCE and Cited1Cre mice
To analyze the efficiency of the Cre, Foxd1GCE/+, Six2GCE/+ or Cited1Cre/+ mice were
crossed with tdTomato reporter mice (R26tdTomato/tdTomato) expressing the loxP-Stop-loxP
tdTomato transgene. Cre+; R26tdTomato/+ embryos were induced with tamoxifen (1 or 3 mg /
40g body weight) at E11.5 or E14.5 during mid-gestation. CITED1 expression does not
become robust until E14.5, therefore we selected E14.5 and E17.5 as the time point for
tamoxifen induction in Cited1Cre mice. Embryonic kidney sections were prepared for
histology analysis at E19.5.

2.1.3 Generation of the mouse tumor cohorts with progenitors targeted
To generate the tumor cohorts, Cre+; Wt1+/- males were bred with females Wt1fl/fl;H19-/(Fig. 2.1 A) or Wt1fl/fl; β-cateninex3fl/fl (Fig. 2.1 B) or β-cateninex3fl/ex3fl (Fig. 2.1 C). Pregnant
mice were injected with tamoxifen (0.5, 1 or 3 mg / 40g BW) intraperitoneally to activate the
inducible CRE in fetal kidney progenitors (Table 3). For Foxd1GCE, tamoxifen was
administered at E11.5. For Six2GCE, tamoxifen was administered at E11.5 or E14.5. The
Cited1Cre transgene is expressed in the liver at E14.5 but not at E17.5, and β-CATENIN
activation in the CITED1+ liver progenitors at E14.5 led to the development of hepatocellular
carcinoma and hepatoblastoma in 90% of mutants at early ages (Mokkapati et al., 2014). To
avoid this competing phenotype and cause of death for our Wilms tumor study, E17.5 was
selected as the time point for tamoxifen injection for the Cited1Cre-Wt1-β-catenin cohort
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generation. Wt1 ablation by Cited1Cre and Igf2 up-regulation did not result in a detectable
liver phenotype with tamoxifen injection at E14.5, therefore we injected tamoxifen at E14.5
for Cited1Cre-Wt1-Igf2 cohort generation. Mutant mice Cre+; Wt1+/fl or Wt1-/fl or Wt1+/+; βcateninexon3+/fl or Cre+; Wt1-/fl; H19+/-m were monitored for tumor development.
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A

Cre / +

Male

Wt1 + / -

X

Cre / +; Wt1 + / -

X

Wt1 fl / fl; H19 - / -

Tamoxifen injection

Female

F-Wt1-Igf2 or
S-Wt1-Igf2 or
C-Wt1-Igf2
Tumor monitor

Cre / +; Wt1 - / fl; H19 + / -m
Cre / +; Wt1 + / fl; H19 + / -m
Wt1 - / fl; H19 + / -m

Control

Wt1 + / fl; H19 + / -m

B Male

Cre / +; Wt1 + / -

X Wt1 fl / fl; β-catenine3fl/e3fl Female

Tamoxifen injection
Cre / +; Wt1 - / fl; β-catenine3fl/+
Cre / +; Wt1 + / fl; β-catenine3fl/+

S-Wt1-βCat or
C-Wt1-βCat or
F-Wt1-βCat
Tumor monitor

Wt1 - / fl; β-catenine3fl/+

Control

Wt1 + / fl; β-catenine3fl/+

C Male

Six2GCE/+

X β-catenine3fl/e3fl

Female

Tamoxifen injection
Six2GCE/+; β-catenine3fl/+
β-catenine3fl/+

S-βCat
Tumor monitor
Control

Figure 2.1 Schematic diagram of mouse crosses for cohort generation
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2.2 Histological, immunohistochemical, and Western blot analysis
Tumor and kidney tissue specimens were fixed in 4% paraformaldehyde, embedded in
paraffin, and cut into 5-µm sections. Hematoxylin and Eosin (H&E), immunohistochemical
and immunofluorescent staining and Western blot analysis of proteins were performed as
described previously (Hu et al., 2010). Antibodies specific for WT1 (sc-192, Santa Cruz
Biotechnology) (1:100), KI67 (ab15580, Abcam) (1:200), pHH3 (06-570, Upstate
Biotechnology) (1:200), β-CATENIN (610154 BD Biosciences) (1:200), DLK1 (sc-8624
Santa Cruz Biotechnology) (1:100), CITED1 (9219 FisherScientific) (1:100), SIX2 (11562-1AP, Proteintech) (1:100), PAX2 (PRB-276P Covance) (1:200), NCAM (C9672 Sigma)
(1:200), E-CADHERIN (3195, Cell Signaling Technology) (1:200), K-CADHERIN (ab79005,
Abcam) (1:200), VIMENTIN (V2258 Sigma) (1:100), COLLAGEN IV (AB756P Chemicon)
(1:100), CYCLIN D1 (sc-753 Santa Cruz Biotechnology) (1:100), C-MYC (9E10 Santa Cruz
Biotechnology) (1:100), ERK 1/2 (4377, Cell Signaling Technology) (1:100), pERK 1/2
(4376, Cell Signaling Technology) (1:100), and pAKT (4051S Cell Signaling Technology)
(1:100) were used.

2.3 β-gal staining
Freshly dissected kidneys or slides made from OCT-embedded frozen tissues were fixed
in fixation buffer (0.2% glutaraldehyde, 2% formalin, 5 mM EGTA, 2 mM MgCl2 in 0.1 M
phosphate buffer) for 30 min to 1 hour at room temperature. Samples were rinsed in rinse
buffer (0.1% sodium deoxycholate, 0.2% NP40, 2 mM MgCl2 in 0.1 M phosphate buffer).
Then samples were stained at 4oC overnight in staining solution (1 mg/ml X-gal, 5 mM K
ferricyanide and 5 mM ferrocyanide in rinse buffer). After staining, tissues or slides were
rinsed and postfixed in 4% paraformaldehyde. Slides were counterstained with eosin for
histological analysis.
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2.4 Kidney rudiment culture
Pregnant mice were injected intraperitoneally at E11.5 with tamoxifen at a dose of
3mg/40g body weight. Kidney rudiments were dissected out of embryos at E12.5 or E13.5.
Mutant and control rudiments were cultured on a trans-well plate (Transwell) with media
containing 1μM 4-OH-TM (Sigma-Aldrich), 10% fetal bovine serum (Sigma-Aldrich) and
DMEM (Sigma-Aldrich 10-017-CV) at 37oC as described previously (Hu et al., 2010). During
culture, live imaging pictures of the rudiments were taken every day with an inverted
microscope (Olympus IX71). After culturing for 3 days, the cultured rudiments were rinsed in
PBS and fixed in methanol for whole-mount immunofluorescence staining (Hu et al., 2010).

2.5 Reverse-phase protein array
Protein was extracted from murine tumors and normal kidney tissues and the
concentration of the protein extracts were calculated with Bradford assay (Bio-Rad). The
samples were analyzed by reverse-phase protein arrays (RPPA) analysis as described
previously (Hu et al., 2010). RPPA is a high-throughput method to detect protein expression
with 135 antibodies against common onco-proteins and tumor suppressors
(mdanderson.org). Briefly, protein samples were denatured by SDS buffer, loaded on
nitrocellulose-coated slides, and probed with antibodies. The signals from binding interaction
were detected by DAB colorimetric reaction.

2.6 Fluorescence-activated cell sorting analysis (FACS)
We administered 1 or 3 mg (per 40g body weight) of tamoxifen to pregnant mice in utero
at E11.5, E14.5 or E17.5. Single-cell suspensions from fetal kidneys harvested at E15.5 or
E19.5 from Foxd1GCE/+; R26tdTomato/+, Six2GCE/+; R26tdTomato/+ and Cited1Cre/+; R26tdTomato/+
embryos were prepared as previously described (Kobayashi et al., 2008). Briefly, kidney
tissues were trypsinized at 37oC for 3-5 minutes and mechanically disintegrated into single
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cells by repeated pipetting up and down in DMEM with 10% FBS. The cell suspensions
were washed with PBS containing 2% FBS and filtered through 70 µm pore filter (BD
Falcon). Cells expressing tdTomato were isolated by using a BD FACS Aria high-speed
digital cell sorter (BD Biosciences). Cell suspensions from littermate kidneys without Cre
served as negative controls.

2.7 Quantitative real-time PCR
Tumor or kidney tissue specimens or isolated tdTomato-positive cells were flash-frozen
in liquid nitrogen. RNA was extracted from specimens or cell pellets using the RNAqueous4PCR kit (Ambion AM1914). The concentration of RNA was determined using the Nanodrop
spectrophotometer (Nanodrop ND-1000). RNA was then converted to cDNA using reverse
transcription reagents (Applied Biosystems). Real-time (RT)-PCR was performed using
SYBR Green PCR Master Mix (Applied Biosystems) with a 7900HT sequence detection
system (Applied Biosystems).

2.8 Statistical analysis
The Student t-test or analysis of variance was used to analyze RT-PCR results. Results
were presented as mean value with standard deviation. P-values less than 0.05 were
considered statistically significant.
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2.9 qRT-PCR Primers
Gene

5' to 3'

Eya1-F

CATAGCCGACTGAGTGGTAGT

Eya1-R

GCTCTGTTTTAACTTCGGTGCC

Osr1-F

TACTCTTTCCTTCAGGCAGTGA

Osr1-R

GATCGAGGCAAGTGCATGG

Hoxa11-F

TTTGATGAGCGTGGTCCCTG

Hoxa11-R

AGGAGTAGGAGTATGTCATTGGG

Pax2-F

AAGCCCGGAGTGATTGGTG

Pax2-R

CAGGCGAACATAGTCGGGTT

Wnt4-F

AGACGTGCGAGAAACTCAAAG

Wnt4-R

GGAACTGGTATTGGCACTCCT

CyclinD1-F

GCGTACCCTGACACCAATCTC

CyclinD1-R

CTCCTCTTCGCACTTCTGCTC

Jag1-F

CCTCGGGTCAGTTTGAGCTG

Jag1-R

CCTTGAGGCACACTTTGAAGTA

E-cadherin-F

ACTGTGAAGGGACGGTCAAC

E-cadherin-R

GGAGCAGCAGGATCAGAATC

Titin-F

TCAAGGAGGAAGCGTCCAAAG

Titin-R

GACTTCTTCGGATGCCTGTGA

Actin a1-F

CCCAAAGCTAACCGGGAGAAG

Actin a1-R

CCAGAATCCAACACGATGCC

Axin2-F

TGACTCTCCTTCCAGATCCCA

Axin2-R

TGCCCACACTAGGCTGACA

Wif1-F

TCTGGAGCATCCTACCTTGC

(Basta et al., 2014)

PrimerBank ID 6754226a1

PrimerBank ID 6680868a1

PrimerBank ID 7305197a1

PrimerBank ID 19388004a1

PrimerBank ID 33563240a1

PrimerBank ID 6755999a1
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Wif1-R

ATGAGCACTCTAGCCTGATGG

Cyclin E-F

GTGGCTCCGACCTTTCAGTC

Cyclin E-R

CACAGTCTTGTCAATCTTGGCA

Cxxc4-F

CTGCCCGCAGAATCATTCCT

Cxxc4-R

CAGACGCCACAGTTGATGAG

Pitx2-F

ACCCCGGCTATTCGTACAAC

Pitx2-R

GAGGACAGGGGATTGACGTTC

Dlk1-F

AGTGCGAAACCTGGGTGTC

Dlk1-R

GCCTCCTTGTTGAAAGTGGTCA

Hmga2-F

GAGCCCTCTCCTAAGAGACCC

Hmga2-R

TTGGCCGTTTTTCTCCAATGG

Dkk2-F

CTGATGCGGGTCAAGGATTCA

Dkk2-R

CTCCCCTCCTAGAGAGGACTT

NCAM-F

ACCACCGTCACCACTAACTCT

NCAM-R

TGGGGCAATACTGGAGGTCA

Pax8-F

ATGCCTCACAACTCGATCAGA

Pax8-R

ACAATGCGTTGACGTACAACTT

Stim1-F

TGACAGGGACTGTACTGAAGATG

Stim1-R

TATGCCGAGTCAAGAGAGGAG

Nfat4-F

CAAGATGGAAGACCTCATTGG

Nfat4-R

GGGAGGAACTTCAAGGACAA

CD15-F

TGGTACTACGCGTGTTCGAC

CD15-R

CCAGGGCTTTGCCAGTTA

CD248-F

CAACGGGCTGCTATGGATTG

CD248-R

GCAGAGGTAGCCATCGACAG

PrimerBank ID 1724116a1

PrimerBank ID 12838136a1

PrimerBank ID 30017353a1

PrimerBank ID 31560347a1
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Synaptopodin-F

GGAAAGTGATGACAGCCAGTG

Synaptopodin-R TTTTCGGTGAAGCTTGTGCT
Dnmt1-F

AAGAATGGTGTTGTCTACCGAC

Dnmt1-R

CATCCAGGTTGCTCCCCTTG

Sall1-F

CTCAACATTTCCAATCCGACCC

Sall1-R

GGCATCCTTGCTCTTAGTGGG

Meox2-F

TGTCCTACCCCGAACTCTCC

Meox2-R

GTGCCAGTTGCTTTGCAGA

Pax3-F

TTTCACCTCAGGTAATGGGACT

Pax3-R

GAACGTCCAAGGCTTACTTTGT

(Spandidos et al., 2010)
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Chapter 3: Results
Part I: Impact of differentiation state and genetic context on the development of
mouse Wilms tumors
3.1 Expression of the progenitor-specific Cre alleles as determined by GFP reporter
expression
To determine what cells in the undifferentiated renal mesenchyme are able to generate
Wilms tumors, we used progenitor-specific tamoxifen-inducible Cre (stromal progenitor
Foxd1GCE and nephron progenitor Six2GCE and Cited1Cre) to introduce gene mutations
somatically and mosaically into specific cellular compartments of the mouse fetal kidneys.
The expression of CRE and GFP (Cre-Gfp) are both driven by the same promoter. We
examined the Cre-Gfp cassette expression driven by the progenitor-specific gene promoter
at E14.5 by assessing the GFP expression. The Foxd1GCE-Gfp cassette was expressed in
the stromal progenitors surrounding the cap mesenchyme (Fig. 3.1B). The Six2GCE-Gfp
cassette was expressed in the uninduced and induced cap mesenchyme in a bracket
pattern (Fig. 3.1D). The Cited1Cre-Gfp cassette was expressed only in the uninduced cap
mesenchyme (Fig. 3.1, E and F).

40

Foxd1GCE/+

Six2GCE/+

Cited1Cre/+

A

C

E

B

D

F

Figure 3.1 Cre-GFP expression under the control of progenitor-specific
gene promoter.
Kidneys from Foxd1GCE/+ (A and B), Six2GCE/+ (C and D) and Cited1Cre/+ (E
and F) at E14.5. (A and C) Bright field images of whole kidneys. (B) GFP
image of kidney from Foxd1GCE/+ embryo showed that Foxd1-Cre-GFP was
expressed in the stromal progenitors surrounding the cap mesenchyme. (D)
GFP image of kidney from Six2GCE/+ embryo showed that Six2-Cre-GFP was
expressed in the uninduced and induced cap mesenchyme. (E-F) Anti-GFP
antibody staining of kidney sections from Cited1Cre/+ embryo showed that
Cited1-Cre-GFP was expressed in the uninduced cap mesenchyme. Dapi
staining shows the nuclear staining of cells.
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3.2 Validation of the fate mapping of the progenitor-specific Cre alleles
We then confirmed the cell fate of the progenitors expressing specific CRE using a β-gal
reporter construct. As reported previously, the stromal progenitors (FOXD1+) generated
interstitial cells, pericytes and mesangial cells (Fig. 3.2, A and B). The nephron progenitors
(SIX2+) gave rise to epithelial cells including comma-shaped bodies, S-shaped bodies,
podocytes, glomeruli, proximal tubules and distal tubules (Fig. 3.2, C and D). These results
confirmed the cell lineage of Foxd1GCE/+ labeled stromal progenitors and Six2GCE/+ marked
nephron progenitors in the mixed genetic background of our mouse strains.
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Foxd1GCE/+; R26βgal/+
A

Six2GCE/+; R26βgal/+
C

Tm E11.5

cb
sb
I
p
I

m

dt

D

B

pt

Tm E14.5

pd
I
g
sb
cb

Figure 3.2 Lineage tracing of the stromal (Foxd1+) progenitors and
nephron (Six2+) progenitors.
β-gal staining of kidney sections from Foxd1GCE/+; R26βgal/+ (A and B) and
Six2GCE/+; R26βgal/+ (C and D). Kidney sections at E14.5 (A) and E19.5 (B)
showed that β-gal labeled cells derived from Foxd1GCE included interstitial
cells (I), pericytes (p) and mesangial cells (m).
Kidney sections at E14.5 (C) and E19.5 (D) showed that β-gal labeled cells
derived from Six2GCE were in comma-shaped bodies (cb), S-shaped bodies
(sb), podocytes (pd), glomeruli (g), proximal tubules (pt) and distal tubules
(dt). Tm: tamoxifen. Scale bars: 100 µm.

43

3.3 Estimation of the efficiency of the progenitor-specific CRE
The efficiency of the progenitor-specific CRE recombinase was analyzed at E19.5 by
using the fluorescent protein reporter, tdTOMATO. Similar results were observed using the
tdTOMATO reporter and β-gal staining. With tamoxifen injection at E11.5, tdTOMATO
induced by Foxd1GCE was expressed in stromal progenitors, interstitial cells and pericytes
(Fig. 3.3 A). Six2GCE was efficient in recombination when tamoxifen injection was at either
E11.5 or 14.5 (Fig. 3.3 B and C). Six2GCE induced tdTOMATO was expressed in nephron
progenitors, renal vesicles, comma-shaped bodies, S-shaped bodies and tubules (Fig. 3.3 B
and C). Cited1Cre/+ was also efficient in recombination with tamoxifen injection at either
E14.5 or 17.5 (Fig. 3.3 D and E). Cited1Cre induced tdTOMATO expression was mainly in
nephron progenitors and early stage of epithelial differentiation structures (Fig. 3.3 B and C),
due to the short time window between tamoxifen injection and reporter expression analysis.
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tdTomato / Dapi

A

Foxd1GCE

Six2GCE

Cited1Cre

3mg Tm at E11.5

1mg Tm at E11.5

3mg Tm at E14.5

D

B

3mg Tm at E14.5

C

1mg Tm at E17.5

E

Figure 3.3 TdTomato reporter showing efficient recombination and
specific cell fate from Foxd1GCE, Six2GCE and Cited1Cre.
tdTomato reporter imaging of kidney sections at E19.5 from Foxd1GCE/+ (A),
Six2GCE/+ (B and C) and Cited1Cre (D and E) after tamoxifen (Tm) injection
with indicated conditions. Scale bars: 200 µm.
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To quantitatively assess the frequency of recombination by the CRE recombinase, we
counted the percentage of tdTOMATO labeled cells in the whole kidneys from Cre+;
R26tdTomato/+ embryos by FACS assay. Single-cell suspensions from fetal kidneys harvested
at E15.5 or E19.5 were sorted for tdTOMATO expression (Table 2). tdTOMATO+ cells were
easily distinguished and separated from the tdTOMATO- cells as shown in a representative
FACS sorting plot (Fig. 3.4 A). FACS analysis at E19.5 showed that about 7% of cells were
labeled with tdTOMATO by Foxd1GCE, 30-34% by Six2GCE, and 5-7% by Cited1Cre (Table 2
and Fig. 3.4B). With Cited1Cre, tamoxifen injection at E14.5 or E17.5 did not seem to affect
the frequency of tdTOMATO+ cells (6.8% and 5.1% respectively), although the frequency
was slightly higher when tamoxifen injection was earlier (Table 2 and Fig. 3.4 B). We also
compared the percentage of tdTOMATO+ cells when analyzed at different time points with
the same conditions of tamoxifen administration. For Foxd1GCE and Six2GCE, tdTOMATO+
cells were assessed at E15.5 and E19.5, and a very similar percentage of tdTOMATO
expressing cells were detected (7.1% vs. 7% and 33.7% vs. 30.2%) (Table 2 and Fig. 3.4
B). Altogether, efficient recombination was achieved with the tamoxifen injection conditions
we used in this study for Foxd1GCE, Six2GCE and Cited1Cre.
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Table 2. Conditions of Tamoxifen injection used to quantify
the Cre efficiency and percentages of tdTomato+ cells
targeted by progenitor-specific Cre

Cre

Foxd1GCE

Time point of
Tm injection

E11.5

E11.5

Tm dosage

FACS

tdTomato+
cells %

E15.5

7.1

E19.5

7.0

E15.5

33.7

E19.5

30.2

3 mg

1 mg

Six2GCE
E14.5

3 mg

E19.5

30.0

E14.5

1 mg

E19.5

6.8

E17.5

1 mg

E19.5

5.1

Cited1Cre
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A

B

Tm 1
1
3
E 11.5 11.5 14.5

1
1
14.5 17.5

3
3
11.5 11.5

E 15.5 19.5 19.5

19.5 19.5

15.5 19.5

Figure 3.4 FACS analysis of embryonic kidney cell suspension for
tdTomato+ cells.
(A) Representative dot-plot of tdTomato+ cells from single cell suspension
of Cited1Cre; R26tdTomato/+ kidney at E19.5 after 3 mg/40g BW Tm
treatment at E14.5. (B) FACS analysis for tdTomato+ cells showing efficient
targeting of stromal progenitor by Foxd1GCE and of nephron progenitor by
Six2GCE or Cited1Cre. In the table below the bar graph, the 1st row shows
the amount of mg of tamoxifen injected per 40g body weight, the 2nd row
shows the injection time and the 3rd row shows the harvest time.
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3.4 Mutated renal stromal progenitors did not result in Wilms tumor
To investigate the cell origin of Wilms tumors in mouse, we used progenitor-specific Cre
and the Cre-Loxp system to mosaically and somatically introduce genetic lesions into
stromal progenitors or nephron progenitors. The genes we genetically engineered are
commonly found mutated in human Wilms tumors, such as Wt1, Igf2 and β-catenin
(reviewed in (Huff, 2007)). Based on the strong association of mutations in each of these
genes found in human Wilms tumors, we combined the genetic mutations into different
groups in our mouse models: Wt1 ablation with Igf2 up-regulation (Wt1-Igf2), β-catenin
stabilization with (Wt1-/fl-β-catS) or without Wt1 ablation (Wt1+/fl-β-catS), and β-catenin
stabilization only (β-catS).
We found that the nephron progenitors but not the stromal progenitors were susceptible
to Wilms tumor development. With the stromal progenitors targeted by Foxd1GCE, none of
the combinations of mutations, F-Wt1-Igf2, F-Wt1-/fl-β-catS or F-Wt1+/fl-β-catS, resulted in
Wilms tumors in the mutant mice (Table 3).
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Table 3. Summary of mutant mouse cohorts

Designation

Genotype

Tamoxifen
Tumor mice /
(mg/40gBW) Mutant mice

F-Wt1-Igf2

Foxd1GCE, Wt1-/fl, H19+/-m

3 at E11.5

0/9

F-Wt1-/fl-β-catS

Foxd1GCE, Wt1-/fl, β-cate3+/fl

3 at E11.5

0 / 17

F-Wt1+/fl-β-catS

Foxd1GCE, Wt1+/fl, β-cate3+/fl

3 at E11.5

0 / 11

S-Wt1-Igf2

Six2GCE, Wt1-/fl, H19+/-m

1 at E11.5

0 / 27

S-Wt1-/fl-β-catS

Six2GCE, Wt1-/fl, β-cate3+/fl

3 at E14.5

8 / 11

S-Wt1+/fl-β-catS

Six2GCE, Wt1+/fl, β-cate3+/fl

3 at E14.5

6 / 12

S-β-catS

Six2GCE, β-cate3+/fl

3 at E14.5

2/5

C-Wt1-Igf2

Cited1Cre, Wt1-/fl, H19+/-m

1 at E14.5

9 / 18

C-Wt1-/fl-β-catS

Cited1Cre, Wt1-/fl, β-cate3+/fl

0.5 at E17.5

9 / 20

C-Wt1+/fl-β-catS Cited1Cre, Wt1+/fl, β-cate3+/fl

0.5 at E17.5

3/7
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3.5 Nephron progenitors targeted with Wt1-β-cats mutations by Cited1Cre or Six2GCE
gave rise to Wilms tumors
In contrast to the stromal progenitors, nephron progenitors (Six2GCE or Cited1Cre),
targeted with β-CATENIN stabilization with (S/C-Wt1-/fl-β-catS) or without Wt1 ablation (S/CWt1+/fl-β-catS) led to the development of Wilms tumors in mice (Table 3). A small cohort of
mice with β-CATENIN stabilization only (β-catS) by Six2GCE (S-β-catS) was also generated
and the mutant mice also developed Wilms tumors (Table 3). Both unilateral and bilateral
tumors were observed and the tumors were frequently associated with kidney cysts filled
with blood fluid (Fig. 3.5 A-a & b). The S/C-Wt1-/fl-β-catS and S/C-Wt1+/fl-β-catS mutant
cohorts had a significantly decreased survival compared to the control mice (Fig. 3.5 B and
C). The Wt1-/fl-β-catS mutants showed a slightly reduced overall life span compared to the
Wt1+/fl-β-catS mutants, but there was no significant difference (Fig. 3.5 B and C).
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A

S-Wt1--catS
a

C-Wt1--catS
b

C-Wt1-Igf2
c

B

C

Figure 3.5 Development of WT from nephron progenitors.
(A) Gross appearance of tumors from Six2GCE mutants (a), Cited1Cre mutants
(b and c) of the indicated genotypes. (B and C) Kaplan-Meier tumor-free
survival curve showing the incidence of mouse WTs in Six2GCE and Cited1Cre
mutant mice with β-catenin stabilization with and without Wt1 ablation (S-Wt1/fl--cats, S-Wt1+/fl- -cats, C-Wt1-/fl- -cats, and C-Wt1+/fl- -cats) and Wt1
ablation and IGF2 upregulation (C-Wt1-Igf2) in comparison to control mice.
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To confirm that the tumors carried the mutations due to somatic recombination of the
floxed allele(s) the mice carried, we examined the recombination status of the floxed alleles
of β-catenin (β-catex3fl to β-catex3∆) and Wt1 (Wt1fl to Wt1∆) in tumors. PCR analysis detected
the recombined β-catex3∆ in all S/C-Wt1-/fl-β-catS, S/C-Wt1+/fl-β-catS and S-β-catS tumors (Fig.
3.6A). Interestingly, 50% of the tumors from S/C-Wt1-/fl-β-catS and S/C-Wt1+/fl-β-catS mice
had incomplete recombination of the Wt1fl to Wt1∆ allele (Fig. 3.6B). These results and the
observation of tumor development in S-β-catS tumors with wild-type Wt1 (Wt1+/+) suggested
that β-CATENIN stabilization in nephron progenitors was sufficient to generate tumors and
that Wt1 ablation was not required for the development of mouse Wilms tumors once βcatenin was stabilized. β-catS tumors with or without Wt1 ablation (Wt1-/∆, Wt1-/fl, Wt1+/∆,
Wt1+/fl and Wt1+/+) showed very similar phenotypes, histology and gene expression profile as
shown below, therefore Wt1 dosage did not seem to play a role in the tumor development if
β-CATENIN was stabilized. So we collectively designated the S-Wt1-/fl-β-catS and S-Wt1+/flβ-catS tumors as S-Wt1-β-catS tumors, and the C-Wt1-/fl-β-catS and C-Wt1+/fl-β-catS tumors
as C-Wt1-β-catS tumors.
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A
S-Wt1-/fl--catS
T1

T2

S-Wt1+/fl--catS
T1

T2

C-Wt1-/fl--catS
T1

Tail

T2

-catex3+ or fl
-catex3Δ

B
S-Wt1-/fl--catS
T1

T2

S-Wt1+/fl--catS
T1

T2

C-Wt1-/fl--catS
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Figure 3.6 PCR detection of  -catex3Δ andWt1Δ in tumors
PCR analysis confirming the presence of gene mutations of the -catex3Δ in
S/C-Wt1-/fl-β-catS and S/C-Wt1+/fl-β-catS tumors, and the Wt1Δ in C-Wt1-Igf2
tumors. (A) PCR analysis of DNA from tumors for -catenin wild type or
floxed allele, and exon3 deleted allele (-catex3+ or -catex3fl, & -catex3Δ). (B)
PCR analysis of DNA from tumors showing Wt1fl and Wt1Δ.
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3.6 Nephron progenitors targeted with Wt1-Igf2 mutations by Cited1Cre but not by
Six2GCE generated Wilms tumors
Although Six2GCE targeted nephron progenitors and Cited1Cre targeted un-induced
nephron progenitors, interestingly, the Six2GCE, Wt1-/fl, H19+/-m (S-Wt1-Igf2) mutants did not
develop tumors but the Cited1Cre, Wt1-/fl, H19+/-m (C-Wt1-Igf2) mutants did (Table 3). The CWt1-Igf2 mutants developed circumscribed unilateral tumors at the periphery of the kidney
(Fig. 3.5 A-c). PCR analysis detected the recombined Wt1∆ in all C-Wt1-Igf2 tumors (Fig.
3.6B). The C-Wt1-Igf2 mutant cohort had a significantly decreased survival compared to the
control mice (Fig. 3.5 C).

3.7 In nephron progenitors, different sets of mutations resulted in Wilms tumors with
different histologies
With the same set of genetic alterations in nephron progenitors targeted with different
Cre alleles, S-Wt1-β-catS tumors and C-Wt1-β-catS tumors showed very similar histology
(Fig. 3.7 C-F). These tumors presented with an epithelial histology, mainly composed of
epithelial elements surrounded by blastemal and stromal elements (Fig. 3.7 A-F). In the
tumors, the primitive epithelial cells formed rudimentary tubules (Fig. 3.7 A, C and E), and
the more differentiated epithelial cells possessed well-formed tubular structures with
cuboidal cells or tall columnar cells (Fig. 3.7 B, D and F). Many of the tubular structures had
luminal esophilic material resembling protein casts. The S-β-catS tumors with wild-type Wt1
also had a very similar histology to S-Wt1-β-catS and C-Wt1-β-catS tumors with varying
degree of Wt1 gene dosage (Fig. 3.7 A-F).
By contrast, with the same nephron progenitor cell origin as S/C-Wt1-β-catS tumors, the
C-Wt1-Igf2 tumors were characterized by a triphasic histology comprised of undifferentiated
blastemal nodules, differentiating epithelial tubules, and stromal cells as did the UbCre-Wt1Igf2 tumors in previously published model with a Ubiquitous Cre-ERTM (Fig. 3.7 G-H).
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Figure 3.7 Histology of WTs from Six2GCE and Cited1Cre mutant mice.

H&E staining of WT sections of S-β-catS, S-Wt1-β-catS, C-Wt1-β-catS, and CWt1-Igf2 mice. The S-β-catS (A&B), S-Wt1-β-catS (C&D), and C-Wt1-β-catS
(E&F) tumors had a very similar epithelial histology. Rosettes lack of nuclear
concentration at the center were present in S-β-catS (A), S-Wt1-β-catS (C), and
C-Wt1-β-catS (E) tumors. Predominant tubules with cuboidal or columnar cells
were present in S-β-catS (B), S-Wt1-β-cateS (D), C-Wt1-β-catS (F) tumors. By
contrast, C-Wt1-Igf2 (G) tumors had a triphasic histology with blastema,
epithelia and stromal elements. (H) Triphasic histology of UbCre-Wt1-Igf2
tumors. Scale bars: 100 µm.
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3.8 S/C-Wt1-β-catS and C-Wt1-Igf2 mouse tumors were proliferative
To characterize the proliferation profile of the tumors, Ki67 IHC staining was performed.
The S-Wt1-β-catS, C-Wt1-β-catS and C-Wt1-Igf2 tumors displayed the tumors cells were
actively proliferating as assessed by Ki67 staining. However, the S-Wt1-β-catS and C-Wt1-βcatS tumors had proliferative cells mostly in their epithelial elements (Fig. 3.8) whereas the
C-Wt1-Igf2 tumors had a high proportion of proliferative cells in the blastemal and epithelial
elements and some in the stromal (Fig. 3.8).
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Figure 3.8 WTs from Six2GCE and Cited1Cre mutant mice were
highly proliferative.
Ki67 IHC staining of tumor sections from control , S-Wt1-β-catS,
C-Wt1-β-catS, and C-Wt1-Igf2 tumors. Scale bars: 50 µm.
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3.9 Wt1-β-catS and Wt1-Igf2 tumors showed different RNA expression of epithelial
differentiation markers
Different subsets of human Wilms tumors had various expression profiles of
developmentally regulated genes (Gadd et al., 2012). One subset histologically and
molecularly corresponded to a differentiated epithelial stage of renal mesenchyme, while
certain other subsets showed a histology and gene expression profile arrested at an early
stage of renal mesenchyme (Gadd et al., 2012). In our mouse models, the S/C-Wt1-β-catS
tumors showed an epithelial histology whereas the C-Wt1-Igf2 tumors had a less
differentiated blastemal predominant histology. Therefore to examine whether, with the
same nephron progenitor cell origin (SIX2+ or CITED1+), S/C-Wt1-β-catS tumors and C-Wt1Igf2 tumors had different expression of developmentally regulated genes, we characterized
the gene/protein expressions of various differentiation stage markers in the tumors with
qRT-PCR and IHC assays.
Detection of RNA expression in these tumors using qRT-PCR demonstrated that the
S/C-Wt1-β-catS and S-β-catS tumors had very low expression of the early mesenchyme
markers such as Eya1, Osr1, Hoxa11, and Pax2, which are essential for the function and
survival of the undifferentiated metanephric mesenchyme (Fig. 3.9). Compared to the S/CWt1-β-catS and S-β-catS tumors, C-Wt1-Igf2 tumors had a significantly higher expression of
these markers at early stage of renal mesenchyme differentiation (Fig. 3.9).
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Figure 3.9 Comparison of gene expression of early mesenchyme
markers in WTs of Six2GCE and Cited1Cre mutant mice.
qPCR analysis of intermediate mesenchyme and early metanephric
mesenchyme markers in mouse tumors showed very low expression of
these markers in S/C-Wt1-β-catS and S-β-catS tumors, and a significant
higher expression in C-Wt1-Igf2 tumors.
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Intermediate epithelial differentiation markers were also analyzed, such as Wnt4 and
CyclinD1, which are specifically expressed in the renal vesicle, and Jag1, a marker in
proximal tubule epithelium which is more differentiated than the renal vesicle. The qRT-PCR
results showed that the S/C-Wt1-β-catS and S-β-catS tumors had low expression of Wnt4
and CyclinD1, while C-Wt1-Igf2 tumors had a significantly increased expression of these
precursor epithelial markers (Fig. 3.10). The S/C-Wt1-β-catS and S-β-catS tumors had lower
expression of Jag1 than C-Wt1-Igf2 tumors, but the difference was not statistically significant
(Fig. 3.10). In contrast, there was no difference in the mRNA expression level of E-cadherin
between S/C-Wt1-β-catS, S-β-catS and C-Wt1-Igf2 tumors (Fig. 3.10).
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Figure 3.10 Comparison of gene expression of epithelia precursor
and epithelia markers in WTs of Six2GCE and Cited1Cre mutant mice.
qPCR analysis showed that S/C-Wt1-β-catS and S-β-catS tumors had a
low level of expression of markers in post-induction renal vesicle (Wnt4
and CyclinD1) and proximal tubule (Jag1). By contrast, C-Wt1-Igf2
tumors had a significant higher expression in Wnt4 and CyclinD1,
increased but not significant higher expression of Jag1. There was no
difference in RNA expression of terminal epithelial differentiation marker
E-cadherin between these tumors.
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3.10

Wt1-β-catS and Wt1-Igf2 tumors showed slightly increased expression of

muscle differentiation genes when compared to expression in normal kidneys
Histologic examination of human Wilms tumors with WT1 mutation have shown ectopic
muscle elements in the tumors, and genes involved in muscle differentiation were found upregulated in Wilm tumors with Wt1 mutations or Wnt/β-catenin activation (Fukuzawa et al.,
2004). Therefore, we checked gene expression of the muscle differentiation markers in
mouse tumors. qRT-PCR analysis showed that, compared to normal kidneys, the S/C-Wt1β-catS, S-β-catS and C-Wt1-Igf2 tumors had a slightly increased expression of myogenesis
markers, eg. Titin and Actin-α1, but the differences were not significant (Fig. 3.11).
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Figure 3.11 qPCR analysis of gene expression of muscle cell
differentiation markers in WTs of Six2GCE and Cited1Cre mutant
mice.
The S/C-Wt1-β-catS, S-β-catS and C-Wt1-Igf2 tumors had a slightly
higher expression of markers in myogenesis, Titin and Actin-α1, than
the normal adult kidneys.
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3.11

S/C-Wt1-β-catS and C-Wt1-Igf2 tumors showed different protein expression

pattern of differentiation markers
Examination of protein expression level and subcellular localization of lineage markers
by IHC staining showed that the S-Wt1-β-catS and C-Wt1-β-catS tumors expressed nephron
progenitor cell markers, Cited1 and Six2, in their epithelial elements (Fig. 3.12). These
tumors also expressed Dlk1 in the epithelial cells and some stromal cells (Fig. 3.12). Dlk1 is
a stem cell marker and is highly expressed in blastemal component in human Wilms tumors
with myogenesis (Fukuzawa et al., 2005). However, the tumors did not express Pax2 which
was robustly expressed in the undifferentiated metanephric mesenchyme (Fig. 3.12 and
3.22). In the S-Wt1-β-catS and C-Wt1-β-catS tumors, very few epithelial cells expressed
CYCLIND1, a protein specifically expressed in the renal vesicle (Fig. 3.13). However, the
tumor epithelial cells expressed E-cadherin, a terminally differentiated epithelial marker (Fig.
3.13). These results suggested that the S-Wt1-β-catS and C-Wt1-β-catS tumors preserved
expression of nephron progenitor markers but also expressed markers of a later stage of
epithelial differentiation.
In comparison, C-Wt1-Igf2 tumors expressed progenitor makers, Cited1 and Six2, and
mesenchyme markers, Dlk1 and Pax2, in the blastemal and epithelial cells (Fig. 3.12), and
the epithelial precursor marker CyclinD1 in some of the epithelial components (Fig. 3.13).
However, they did not express E-cadherin (Fig. 3.13). These results suggested that the CWt1-Igf2 tumors were more mesenchymal than the S/C-Wt1-β-catS tumors and that they
maintained the progenitor-like features of their tumor initiating cells.
Altogether, although S/C-Wt1-β-catS tumors and C-Wt1-Igf2 tumors arose from the same
cell origin of nephron progenitors, the different genetic lesions (Wt1-β-catS vs. Wt1-Igf2) in
these mutant mice resulted in different types of tumors, with the S/C-Wt1-β-catS tumors
more epithelially differentiated while the C-Wt1-Igf2 tumors display mesenchymal elements
and less differentiated epithelial elements and high expression of the mesenchyme genes.
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Figure 3.12 Expression of nephron progenitor markers and mesenchyme markers of WTs
from Six2GCE and Cited1Cre mutants.
IHC staining of Cited1, Six2, Dlk1 and Pax2 on sections from normal kidneys, S-Wt1-β-catS tumors,
C-Wt1-β-catS tumors and C-Wt1-Igf2 tumors. Scale bars: 100 µm.
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Figure 3.13 Expression of epithelia, mesenchyme and cell matrix markers in WTs of Six2GCE and
Cited1Cre mutant mice.
IHC staining for CyclinD1, E-cadherin, Vimentin, and Collagen IV of sections from normal kidneys, SWt1-β-catS tumors, C-Wt1-β-catS tumors and C-Wt1-Igf2 tumors. Scale bars: 100 µm.
67

3.12

Expression of human WT blastemal marker and cellular matrix markers in S/C-

Wt1-β-catS and C-Wt1-Igf2 tumors
Vimentin expression is observed in the blatemal and stromal components of human
Wilms tumors. Interestingly, the S-Wt1-β-catS and C-Wt1-β-catS tumors expressed Vimentin
in tumor epithelial cells (Fig 3.13). The C-Wt1-Igf2 tumors expressed Vimentin in blastemal,
epithelial and stromal components in a diffuse manner (Fig. 3.13).
IHC staining of cellular matrix marker on tumor sections showed positive staining for
COLLAGEN IV in the extracellular matrix of the stromal cells in the S-Wt1-β-catS tumors, CWt1-β-catS tumors and C-Wt1-Igf2 tumors (Fig. 3.13).

3.13

β-catenin signaling and Wt1 target gene expression in mouse tumors

In the mutant mice, β-catenin stabilization or Wt1 ablation was introduced. To determine
whether their downstream signaling or expression of target genes was affected by the
genetic alterations, we examined the activity of the Wnt/β-catenin pathway and the
expression of Wt1 transcriptional targets in the mouse tumors.

3.13.1 Nuclear accumulation of β-CATENIN protein in S/C-Wt1-β-catS tumors and
increased cytoplasmic expression of β-CATENIN in C-Wt1-Igf2 tumors
IHC staining of β-CATENIN showed that the S/C-Wt1-β-catS tumors and the C-Wt1-Igf2
tumors had dramatically increased expression of β-CATENIN protein when compared to
normal kidneys (Fig. 3.14). The S/C-Wt1-β-catS tumors showed a high level of β-CATENIN
expression in the epithelial elements, and a large portion of these cells had β-CATENIN
nuclear accumulation, confirming the stabilization of β-CATENIN in the β-catS tumor cells
(Fig. 3.14). In comparison, β-CATENIN was expressed mainly in the cytoplasm of blastemal,
epithelial and stromal components in the C-Wt1-Igf2 tumors (Fig. 3.14).
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Figure 3.14 β-catenin signaling activity in WTs from Six2GCE and Cited1Cre mutant mice.
IHC staining of β-catenin and downstream target C-myc of sections from normal kidneys, S-Wt1-β-catS
tumors, C-Wt1-β-catS tumors and C-Wt1-Igf2 tumors. Scale bars: 100 µm.
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3.13.2 WNT/β-CATENIN signaling in mouse tumors
The RNA of β-CATENIN direct target Axin2 was expressed in both S/C-Wt1-β-catS
tumors and C-Wt1-Igf2 tumors, compared to the very low expression of Axin2 in control
kidneys. The S/C-Wt1-β-catS tumors showed a slightly higher expression of Axin2 than the
C-Wt1-Igf2 tumors (Fig. 3.15). This result is in agreement with the stabilization and nuclear
accumulation of β-CATENIN protein in S/C-Wt1-β-catS tumors (Fig. 3.14). WNT/β-CATENIN
inhibitor Wif1 was also elevated in S/C-Wt1-β-catS tumors and C-Wt1-Igf2 tumors compared
to control kidneys (Fig. 3.15). The S/C-Wt1-β-catS tumors, however, had a much higher
expression of Wif1 than did the C-Wt1-Igf2 tumors, suggesting a negative feedback loop
responding to the stabilized β-CATENIN. Therefore, both S/C-Wt1-β-catS and C-Wt1-Igf2
tumors displayed increased WNT/β-CATENIN activity, but the activity was higher in S/CWt1-β-catS tumors than C-Wt1-Igf2 tumors. However, S/C-Wt1-β-catS tumors had low
expression of other canonical targets of the β-CATENIN pathway, e.g., protein expression of
C-MYC and transcription of Cxxc4 (Fig. 3.14 & 3.15). Thus, we propose that β-CATENIN
signaling promotes tumor growth through different sets of targets or acts through noncanonical cell-cell adhesion pathways.
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Figure 3.15 qPCR analysis of β-Catenin signaling and Wt1 target
expression in WTs from Six2GCE and Cited1Cre mutant mice.
qPCR results showed that compared to normal kidneys, β-catenin
pathway targets Axin2 and Cyclin E1 and Wnt/β-catenin inhibitors Wif1
were increased in S-Wt1-β-catS tumors, and Wt1 targets CXXC4 and
Cyclin E1 were upregulated in C-Wt1-Igf2 tumors.
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3.13.3 Wt1 targets in mouse tumors
Cyclin E is a target of β-catenin transcriptional activation and Wt1 transcriptional
repression (Loeb et al., 2002). RNA expression of Cyclin E was increased in S/C-Wt1-β-catS
tumors and C-Wt1-Igf2 tumors compared to control kidneys (Fig. 3.15). CXXC4 upregulation
was found in WT1 mutated human Wilms tumors (unpublished data in our lab). We therefore
measured the transcription of Cxxc4 and observed that Cxxc4 was significantly increased in
C-Wt1-Igf2 tumors in comparison to S/C-Wt1-β-catS tumors and control kidneys (Fig. 3.15).

3.14

S/C-Wt1-β-catS and C-Wt1-Igf2 tumors did not have increased pERK and pAKT

expression
The MAPK/ERK signal transduction pathway has been shown to be activated in mouse
Wilms tumor models (Clark et al., 2011; Hu et al., 2010). To test whether this pathway was
altered in our mouse tumors, we performed IHC staining of the effectors in MAPK/ERK
signaling. However, we did not detect positive staining for pERK and pAKT in S/C-Wt1-βcatS tumors and C-Wt1-Igf2 tumors by IHC (Fig. 3.16).
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Figure 3.16 Expression of pERK and pAKT in WTs from Six2GCE and Cited1Cre mutant mice.

IHC staining of sections from normal kidneys, S-Wt1-β-catS tumors, C-Wt1-β-catS tumors and CWt1-Igf2 tumors showed negative staining of pERK and pAKT in tumors. Scale bars: 100 µm.

73

3.15

Proteomic analysis of S/C-Wt1-β-catS and C-Wt1-Igf2 tumors

To identify cancer cell signaling pathways dysregulated in S/C-Wt1-β-catS and C-Wt1Igf2 tumors and pathways contributing to the differences in the differentiation status between
S/C-Wt1-β-catS and C-Wt1-Igf2 tumors, we carried out RPPA analysis. RPPA is a highthroughput proteomic assay which employs probing of a protein array with a panel of
antibodies. The results of this assay demonstrated that the S-Wt1-β-catS tumors, the C-Wt1β-catS tumors and the C-Wt1-Igf2 tumors had a very similar protein expression profile (Fig.
3.17). Tumors targeted by Six2GCE and Cited1Cre were therefore similar in their protein
expression, and β-catS tumors with differential gene dose of Wt1 were also very similar in
their protein expression.
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Figure 3.17 Heat map of the results of RPPA analysis of gene
expression among mouse Wilms tumors.
Clustering with proteins differing among the groups from RPPA analysis
showed similar protein expressions among mouse tumors. Cwb, C-Wt1-/fl-βcatS tumors; cwH, C-Wt1-Igf2 tumors; sb, S-Wt1-/fl-β-catS tumors; swb, SWt1+/fl-β-catS tumors; Wt1NB, control new born kidneys.
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3.16

Correlation of mouse S/C-Wt1-β-catS and C-Wt1-Igf2 tumors to human WT

subsets by gene expression analysis
A previous study has identified different subsets of human Wilms tumors by global gene
expression profile (Gadd et al., 2012). Subset 1 (S1) was identified as epithelial predominant
tumors with gene expression signatures correlated with late differentiation stage, while
Subset 2-5 (S2-5) showed a signature of gene expression associated with early
metanephric mesenchyme and a triphasic histology (Gadd et al., 2012). The differences in
histology and gene expression between S1 and S2-5 were very similar to that between the
mouse S/C-Wt1-β-catS and C-Wt1-Igf2 tumors. Therefore, to find out whether S/C-Wt1-βcatS tumors expressed genes whose expression characterized S1 tumors and whether CWt1-Igf2 tumors expressed genes whose expression characterized a certain subset among
subsets S2-5 tumors, we examined the gene expression pattern in mouse tumors with
selected genes that differentiated the S1 and S2-5 subsets. The qRT-PCR analysis
demonstrated a similar pattern in expression of some genes assessed between human
subsets and our mouse models. For example, the expression of genes Hoxa11, HMGA2
and Dlk1 were lower in S/C-Wt1-β-catS tumors than C-Wt1-Igf2 tumors and also were lower
in S1 than S2-5 (Fig. 3.18). The expression of other selected genes, however, did not show
a clear correlation of the mouse tumors to human subsets (Fig. 3.18). Here we were limited
by the numbers of genes tested and the methods used. Global gene expression analysis
with micro-array and cross-species comparison and clustering approach are needed to
explore the relationships between the mouse tumor models and patient tumor subsets.
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Figure 3.18 Analysis of possible correlation between mouse tumors to human WT subsets.
qRT-PCR analysis of S/C-Wt1-β-catS and C-Wt1-Igf2 tumors with genes differentiating human WT subsets.
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Images are from Gadd, S., Huff, V., Huang, C.C., Ruteshouser, E.C., Dome, J.S., Grundy, P.E., Breslow, N., Jennings, L., Green, D.M., Beckwith, J.B., et al. (2012).
Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study. Neoplasia 14,
742-756.

Part II: Wt1 function in kidney progenitors during development
Wt1 mutations predispose to Wilms tumor development, but the mechanisms by which
Wt1 mutations in the undifferentiated mesenchyme contribute to the cell transformation have
still not been identified. Therefore, we investigated the in vivo function of Wt1 specifically in
kidney stromal and nephron progenitors by somatically deleting Wt1 early during kidney
development.

3.17

Wt1 ablation in stromal progenitors did not affect kidney development

During kidney development, WT1 is expressed in the stromal progenitors and nephron
progenitors in the undifferentiated metanephric mesenchyme (MM). It plays a critical role in
cell survival and apoptosis of MM and MET during kidney development. With the progenitorspecific Cre to conditionally delete Wt1, we could test the biological functions of Wt1 in each
progenitor cell population. We applied a high dose of tamoxifen (6 mg/40 g bw)
intraperitoneally to pregnant mice at E11.5 to ablate Wt1 in a high proportion of progenitors
(Foxd1+ or Six2+).
The Foxd1GCE/+, Wt1 -/fl (F-Wt1) kidneys with Wt1 ablation in stromal progenitors were
examined at E19.5 and did not show a difference in morphology and histology compared to
the controls (Fig. 3.19). The H&E staining showed that the mutant kidneys had the normal
formation of mature nephrons, collecting ducts and stromal cells as in control kidneys (Fig.
3.19). IHC with WT1 staining showed that the F-Wt1 mutant kidneys had normal
development of metanephric mesenchyme, renal vesicles, comma-shaped bodies, Sshaped bodies and glomeruli, similar to that observed in control kidneys (Fig. 3.19).
To confirm that Wt1 ablation did not affect the differentiation and function of stromal
progenitors, we used β-gal as a reporter to track the Wt1-ablated progeny cells derived from
stromal progenitors (Foxd1GCE/+, Wt1 -/fl, R26βgal/+). β-gal staining of mutant kidneys in E19.5
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and 3.5 month-old mice showed that the Wt1 ablated descendent cells from stromal
progenitors retained stromal cell fates and differentiated normally into the interstitial cells,
mesangial cells, pericytes and smooth muscle cells (Fig. 3.20). These results suggested that
Wt1 in stromal progenitors does not seem to play a critical role on nephrogenesis.
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Figure 3.19 Wt1 ablation in stromal progenitors (Foxd1+) did not
affect kidney development.
H&E and Wt1 IHC staining of kidney sections at E19.5 showed that the
mutant F-Wt1 kidneys had normal histology and nephrogenisis shown by
Wt1 positively stained normal metanephric mesenchyme, renal vesicle,
comma-shaped body, S-shaped body and glomeruli as the control. Scale
bars: 200 µm.
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Figure 3.20 stromal progenitors with Wt1 ablation showed normal cell
differentiation.
β-gal staining of kidney sections from E19.5 and 3.5 months old F-Wt1
mutants showed that the β-gal labelled mutant cells differentiated normally
into interstitial cells (i), mesangial cells (m), pericytes (p) and smooth
muscle cells (sm). Scale bars: 100 µm.
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3.18

Wt1 ablation in nephron progenitors resulted in defects in nephrogenesis

In contrast, early Wt1 ablation at E11.5 in the nephron progenitors disrupted
nephrogenesis. Histological examination showed that Six2GCE/+, Wt1 -/fl (S-Wt1) mutant
kidneys at E19.5 had an expanded nephrogenic zone (NZ) where the progenitors resided,
reduced nephron formation, and increased number of stromal cells surrounding the
epithelial structures, compared to the control kidneys (Fig. 3.21). In the control kidneys, the
metanephric mesenchyme condenses to the cap mesenchyme (CM) around the tips of
ureteric buds and the mesenchyme differentiates upon induction by the ureteric buds. The
ureteric buds are usually surrounded by 2-3 layers of CM cells (CITED1+, WT1+ and
PAX2+). However, when Wt1 was ablated in the nephron progenitors, there were increased
layers of CM cells (3-5 layers) around the ureteric buds in S-Wt1 mutants (Fig. 3.21 and
3.22). The cells in the expanded NZ remained proliferative (Ki67+) and maintained the
expression of nephron progenitor cell marker CITED1 and metanephric mesenchyme
marker PAX2 (Fig. 3.22), suggesting that the accumulated CM cells retained their progenitor
cell features. IF staining of WT1 showed that the S-Wt1 kidneys had marked reduction of
comma-shaped bodies, S-shaped bodies and glomeruli (Fig. 3.23). IF staining of ECADHERIN also showed the decreased formation of epithelial structures in the S-Wt1
kidneys (Fig. 3.23). Moreover, the ureteric buds (DBA+) were slightly dilated in the S-Wt1
kidneys, compared to the control (Fig. 3.23).
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Figure 3.21 Wt1 ablation in nephron progenitors resulted in the
mesenchyme expansion and reduced nephrogenesis.
H&E staining of kidney sections at E19.5 showed that the mutant kidneys
had an expanded nephrogenic zone (depth indicated by red arrows) and
decreased formation of nephrons, compared to the control kidneys. Scale
bars: 200 µm.
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Figure 3.22 Nephron progenitors with Wt1 ablation remained
proliferative and maintained progenitor marker expressions.
IF staining of kidney sections at E19.5 with proliferation marker Ki67 and
progenitor markers Cited1 and Pax2. With Wt1 ablation, nephron progenitors
in the expanded NZ were Ki67 positive and maintained the expression of
Cited1 and Pax2. Pax2 was expressed in both progenitors and ureteric bud,
so DBA was used here as a ureteric bud marker to indicate the Pax2+DBAcap mesenchyme cells. Scale bars: 200 µm.
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Figure 3.23 Wt1 ablation in nephron progenitors resulted in
decreased epithelial differentiation.
IF staining of kidney sections at E19.5 showing that the S-Wt1 mutant
kidneys had a remarkable decrease in Wt1expressing comma-shaped
bodies, S-shaped bodies and glomeruli. E-cadherin staining confirmed
the reduced formation of epithelial structures caused by Wt1 ablation in
nephron progenitors. DBA staining showing that the ureteric buds were
slightly dilated in mutant kidneys compared to the control. (Arrow heads
point to epithelial structures) Scale bars: 200 µm.

85

To check whether the phenotype observed in S-Wt1 kidneys at E19.5 was evident at an
earlier stage, we examined kidneys at E15.5. S-Wt1 kidneys at E15.5 also showed an
expansion of the NZ (Fig. 3.24). In the expanded NZ, there were increased cells in the CM
(Fig. 3.24). Cells in the NZ of S-Wt1 kidneys were proliferative (Ki67+) and expressed
CITED1 as shown by IHC staining (Fig. 3.25). Compared to control kidneys, the S-Wt1
kidneys showed decreased formation of K-CADHERIN expressing early epithelial structures
such as renal vesicle, comma-shaped bodies and S-shaped bodies (Fig. 3.25).
In all, these results suggested that Wt1 ablation in the nephron progenitors prevented
cells from differentiating but these cells maintained their progenitor cell state in terms of
proliferation and expression the nephron progenitor markers.
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Figure 3.24 S-Wt1 mutants showed defects in nephrogenesis as
early as at E15.5.
H&E staining of kidney sections from controls and S-Wt1 mutants at
E15.5. The phenotypes of expanded NZ and disturbed epithelial
differentiation were observed as early as E15.5 in mutant kidneys. Scale
bars: 200 µm.
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Figure 3.25 Marker expressions of S-Wt1 mutant kidneys at E15.5.
Ki67 staining showed that in S-Wt1 kidneys the expanded NZ was proliferative.
The cells in the expanded NZ expressed progenitor marker Cited1. Compared
to the controls, the mutant kidneys had fewer K-cadherin expressing early
epithelial structures (*) such as renal vesicle, comma-shaped body and Sshaped body. Scale bars: 200 µm.
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3.19

Lineage tracing of Wt1 ablated nephron progenitors in vivo

To study the fate of Wt1-ablated nephron progenitors, we used β-gal or tdTomato as
reporters to track the mutant cells in S-Wt1 kidneys (Six2GCE/+, Wt1-/fl, R26βgal/+ or Six2GCE/+,
Wt1-/fl, R26tdTomato/+). β-gal staining of mutant kidneys at E15.5 and E19.5 showed that most
of the CM cells were labeled with β-gal, which suggested that the Wt1 ablated progenitors
retained their capacity for self-renewal. Moreover, β-gal was expressed in disorganized
epithelial-like structures with closed lumen compared to normal tubule formation in the
control kidneys (Fig. 3.26). This phenotype may result from abnormal differentiation of the
Wt1 ablated progenitors and possibly disrupted polarization in the cells. Very interestingly,
the mutant kidneys had a few β-gal+ cells present in the kidney stromal, which was not
detected in the control kidneys (Fig. 3.26). Whether this is due to mislocation of Wt1 ablated
cells in the stromal or a trans-differentiation of mutant cells from nephron progenitor cell
origin to a stromal cell fate is not known.
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Figure 3.26 β-gal reporter tracing of Wt1 ablated cells from nephron
progenitor origin.
β-gal was expressed in the self-renewing progenitors in CM, in abnormally
differentiated epithelial structures with closed lumen, and rarely but aberrantly
in the the kidney stromal (arrow heads). Scale bars: 200 µm.
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3.20

Tracing Wt1 ablated cells from nephron progenitors with tdTOMATO reporter

To monitor the behavior of the cells from Wt1 ablated nephron progenitors in real-time,
we used a kidney rudiment culture system to visualize the rudiment growth by imaging
cultures every 30 minutes for 3-4 days to generate time-lapse movies. tdTOMATO reporter
was used to track the mutant cells.
Pregnant mice were injected with 6mg/40g BW tamoxifen at E11.5, then at E13.5 mutant
kidneys Six2GCE/+, Wt1-/fl, R26tdTomato/+ (S-Wt1-tdTomato) and littermate controls Six2GCE/+,
Wt1+/fl, R26tdTomato/+ (S-tdTomato with a wild type Wt1) were dissected out and cultured on
filters with media supplied with tamoxifen so that the floxed allele of Wt1 and R26tdTomato
were recombined in a very high efficiency. The rudiments were placed inside an incubator
equipped with a fluorescent microscope. Live images and tdTOMATO fluorescence images
of the whole kidney rudiment were taken during culture.
Representative images at the 15th and 51st hours of the rudiment culture showed that
the wild type rudiments expressed tdTOMATO reporter robustly in the CM and clusters of
differentiating epithelial cells (Fig. 3.27). However, the mutant rudiment had extended and
elongated CM and lacked formation of epithelial structures (Fig. 3.27). PCR of isolated
tdTOMATO expressing cells showed highly efficient Wt1 ablation in tdTOMATO marked
cells derived from nephron progenitors (Fig. 3.27).
To confirm the phenotype of impaired epithelial differentiation of mutant nephron
progenitors, we characterized the expression of epithelial markers in the rudiments
harvested after 3-day culture with immunofluorescence staining (IF). IF staining showed
WT1 was expressed in cap mesenchyme and epithelial clusters in the control kidneys, while
in the mutant the WT1 expressing cap mesenchyme was expanded, and very few WT1
expressing epithelial clusters were observed (Fig. 3.27). K-CADHERIN staining confirmed a
remarkable decrease of epithelial structure formation in the mutant rudiments (Fig. 3.27).
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Figure 3.27 Tracking and monitoring Wt1 ablated cells from Six2GCE
with tdTomato reporter in kidney rudiment culture
Live field images and tdTomato images of rudiments during culture. PCR of
isolated tdTOMATO+ cells confirmed efficient Wt1 ablation in nephron
progenitor derived cells. IF staining of Wt1 showed mutant cells in cap
mesenchyme were arrested in the MET. K-cadherin staining of the cultured
rudiments confirmed the impaired formation of K-cadherin expressing
epithelial structures.
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To examine whether ureteric bud branching was affected by the differentiation arrested
mesenchyme with Wt1 ablation, we did IF staining of the rudiment with LAMININ, a ureteric
bud marker. We calculated the branching efficiency based on how many branches
developed from the trunk to the bud ends. Branching efficiency of the ureteric bud in the
mutant (Six2GCE/+; Wt1-/fl) was slightly lower than the control with Wt1 haploinsufficiency
(Six2GCE/+; Wt1+/fl) and the control of Wt1 wild type (Wt1+/fl) (p-value=0.03) (Fig. 3.28).
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Figure 3.28 Mutant kidneys showed slightly decreased branching
efficiency.
Laminin staining was used to visualize and highlight the ureteric buds for the
calculation of the branching efficiency. After 3 day culture with tamoxifen, the
mutant kidneys showed slightly less efficient in ureteric bud branching and
slight dilation at the tips of the ureteric buds. Quantification of the ureteric bud
branching efficiency showed that the mutant was not significantly different
from the control Six2GCE/+; Wt1+/fl with Wt1 haploinsufficiency, but was
significantly less efficient in branching than the control Wt1+/fl with wild type
Wt1.
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3.21

Gene expression analysis of kidneys with Wt1 ablation in nephron progenitors

To investigate what potential targets or signaling pathways were affected by WT1 loss of
function in nephron progenitors, we performed qPCR analysis of the mutant and control
kidneys at E19.5. Pregnant mice were injected with tamoxifen at E11.5 to ablate Wt1 with
Six2GCE/+ at E11.5 and kidneys were dissected out and RNA isolated for qRT-PCR analysis.
We tested genes which were identified as markers in human WTs, effectors in Wnt/βCATENIN canonical and non-canonical Ca2+ pathway, differentiation markers in early
mesenchyme and stromal and epithelial differentiation (Fig. 3.29). Among all the genes
tested, two genes showed significant increase in mRNA expression of the mutants
compared to the control (Fig. 3.29): Axin2, a Wnt/β-CATENIN direct target, and, Osr1, an
early mesenchyme marker (Fig. 3.29). These results suggested that Wt1 ablation in nephron
progenitors resulted in increased the Wnt/β-CATENIN signaling, in agreement with a
previous study that showed that Wt1 was a repressor for the Wnt/β-CATENIN pathway
(Chang et al., 2008). The results of Osr1 up-regulation in S-Wt1 kidneys and the presence
of S-Wt1 cells in kidney stromal suggested that Wt1 ablation in the nephron progenitors may
help cells to acquire long-term self-renewal and differentiation plasticity to an earlier lineage,
and potentially prepare the cells to be transformed to a tumor cell.
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Control: Six2GCE; Wt1+/fl
Mutant: Six2GCE; Wt1-/fl

Figure 3.29 Gene expression analysis of S-Wt1 mutant kidneys and control kidneys at E19.5.
qPCR analysis of the S-Wt1 mutant and control kidneys at E19.5 with genes in Human WTs, Wnt/β-Catenin
canonical and non-canonical pathways and differentiation markers.
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3.22

Wt1 ablation in nephron progenitors resulted in fibrosis in adult kidneys

To assess the longer term effects of Wt1 ablation in nephron progenitors, we examined
adult kidneys in 2 month-old mice. The mutant kidneys displayed a thinner cortex and
multiple lesions with tubule dilation (Fig. 3.29). To check whether the cells in the lesion
came from S-Wt1 mutant cells, we used β-gal to track the cells with Wt1 ablation. In the
adult mutants, β-gal reporter was expressed in the tubule cells but not in the cells in the
lesion (Fig. 3.30). This indicated that the lesions may not directly come from Wt1 ablated
nephron progenitors, but they were caused by a secondary response to the Wt1 ablated
cells. Alternatively, negative staining of β-gal in lesions could be due to technical difficulties
in visualizing β-gal staining in lesional cells with little cytoplasm. The cells in the lesions
were positive for Ki67 staining, suggesting they were proliferative (Fig. 3.30). To identify
what type of cells constituted the lesions, we did IHC and IF staining with protein markers.
The cells in these lesions did not express CITED1, SIX2 and K-CADHERIN (Fig. 3.30),
which confirmed that these cells were not persisting nephron progenitor cells. To determine
whether the lesion cells were inflammatory cells, we stained kidney sections with F4/80
(macrophage marker) IF staining. The cells in the lesions were not F4/80 expressing
macrophages (Fig. 3.31). However, these lesion cells were positively stained for VIMENTIN,
suggesting a fibrotic nature of the lesions. PAS positive staining and extensive deposition of
Type IV Collagen in the lesions in the mutant kidneys further confirmed that the lesions were
fibrotic tissues (Fig. 3.31). Therefore, early Wt1 ablation in the nephron progenitors led to
the formation of fibrosis in the adult kidneys, but it is not clear how the fibrotic tissues were
formed.
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Figure 3.30 Wt1 ablation in nephron progenitors results in lesion formation
in adult kidneys
H&E staining of kidney sections from S-Wt1 mutant and control kidneys at 2
months old. Mutants showed a thinner cortex and lesion formation highlighted by
red line. β-gal staining of kidney sections from S-Wt1-β-gal mutant kidneys
showed that the lesions did not express β-gal. IHC staining of kidney sections
showed that cells in the lesions did not express Six2, Cited1 and K-cadherin, but
Ki67. Scale bars: 250 µm.
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Figure 3.31 Lesions in Wt1 ablated adult mutants were fibrotic.
IF staining of adult kidney sections with macrophage marker F4/80 and fibrosis markers Vimentin, Collagen
IV, and Masson’s Trichorme staining. Lesions in the mutants were negative for F4/80 staining but positively
stained for Vimetnin, Masson’s Trichrome and Collagen IV. Scale bars: 200 µm.
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Chapter 4: Discussion
4.1 Cell origin of Wilms tumors in metanephric mesenchyme
Wilms tumor is an embryonal tumor of the kidney. Typically it has a triphasic histology
and is thought to be a malignancy derived from transformed fetal metanephric mesenchyme,
which can variably differentiate and clonally expand to generate the bulk of the tumor.
However, it is not clear yet what type(s) of cells in the undifferentiated metanephric
mesenchyme are the origins of the tumors. Recent global expression analysis of a large
panel of WT patients has identified different subsets of WTs that are distinct in their clinical
outcomes and gene expression profiles. These subsets variably express specific genes that
correspond to early renal mesenchyme or fully differentiated epithelium. These results
suggest that different subsets of WTs may arise from cells transformed at different stages of
differentiation and that the stage of differentiation at which a tumor arises is a major factor in
determining tumor biology and clinical outcomes.
To investigate the malignant potential of different types of cells in the undifferentiated
metanephric mesenchyme, we generated cohorts of mice by using cell-type-specific
tamoxifen-inducible Cre to somatically and mosaically introduce genetic lesions into specific
progenitor cell populations including stromal progenitors (by Foxd1GCE) and nephron
progenitors (by Six2GCE or Cited1Cre). The gene alterations introduced into the mice are
frequently observed in tumors from WT patients and affect genes which are expressed in
the metanephric mesenchyme and play essential roles in kidney development. Using the
Cre-Loxp system, we somatically and mosaically ablated Wt1 in the background of Igf2 upregulation (Wt1-Igf2) or stabilized β-catenin with or without Wt1 ablation (Wt1-β-catenin).
With the gene alterations we introduced, the nephron progenitors but not the stromal
progenitors gave rise to Wilms tumors. During early kidney development, the stromal
progenitors and nephron progenitors are derived from the OSR1+ cells in the metanephros
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and the stromal progenitors and nephron progenitors are fated exclusively (Mugford et al.,
2008b). Based on previous findings that tumor cells retain features of progenitor cellular
origin in brain tumors (Schuller et al., 2008), we initially speculated that targeting the stromal
progenitor would result in the stromal predominant type of Wilms tumors, whereas targeting
the nephron progenitor would lead to the blastemal or epithelial predominant type of Wilms
tumors. We found that targeting the stromal progenitors with either group of gene mutations,
Wt1-Igf2 or Wt1-β-catenin, did not lead to Wilms tumors, suggesting that the stromal
progenitors were refractory to the oncogenic stimulation of Wt1-Igf2 or Wt1-β-catenin
genetic alterations. However, both combinations of gene alterations introduced into the
nephron progenitors resulted in Wilms tumor development, suggesting that the nephron
progenitors are the tumor initiating cells. Moreover, the transformed nephron progenitors
were able to aberrantly differentiate to the different cell types in the tumors such as
blastemal, epithelial, and stromal elements. Altogether, the stromal progenitors and nephron
progenitors with different lineages showed different tumorigenic potentials. This was also the
case in studies of the cell origin of pediatric brain tumors, in which different progenitors
exhibited different susceptibility for tumor transformation and progenitors with different
lineage commitments generated different types of tumors (Swartling et al., 2012). As
development proceeds, progenitors exit the cell cycle and differentiate; however, with
oncogenic stimulation, progenitors acquire the ability to self-renew long-term and remain
proliferative and eventually comprise the bulk of tumors (Yang et al., 2008). The Patched
deletion medulloblastoma model also suggested that the granule lineage is specifically
sensitive to the oncogenic stress of hedgehog signaling, though the multipotent neural stem
cells were targeted (Yang et al., 2008).
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4.2 Stromal progenitors are not at risk of Wilms tumor development
One possible reason for the absence of tumor development from the stromal progenitor
is the intrinsic property of the progenitor itself. Transcriptionally and epigenetically, the
stromal progenitors and nephron progenitors are programmed differently. When stromal
progenitors were targeted with genetic lesions, they may undergo apoptosis or may function
normally with the mutations. We did not test in this study whether stromal progenitors with
mutations underwent apoptosis. However, the resistance of stromal progenitors to
oncogenic stimulation is consistent with our observation from the developmental study that
when stromal progenitors were targeted with Wt1 ablation only, stromal progenitor-derived
cells differentiated normally and kidneys appeared normal. When β-catenin was deleted in
stromal progenitors by using constitutive Foxd1-Cre, the phenotype of the stromal progenitor
derived cells, nephron induction and ureteric bud branching, was normal except for a slightly
thicker cortex and lack of medulla development (Yu et al., 2009). Therefore, although WT1
and β-CATENIN are expressed in the stromal progenitors, normal expression of these
genes may not be important for the stromal progenitors to survive, self-renew, proliferate
and differentiate. In other words, the stromal progenitors are not sensitive to the genetic
manipulations we used here for transformation. More work is required to test whether
additional gene mutations, for example p53 mutations, are needed for cell transformation of
the stromal progenitors. On the other hand, the microenvironment of the tumor initiating cells
is also critical for tumor development. The niche of the stromal progenitor, resulting from the
local paracrine signaling, extracellular cell matrix, angiogenesis and inflammatory cells, may
not favor cell transformation.

4.3 Nephron progenitors are competent to generate Wilms tumors
Gene expression and IHC analysis of human Wilms tumors showed that tumors had a
profile of marker gene expression similar to that of the nephron lineage, including
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expression of SIX2, CITED1 (Murphy et al., 2012), PAX2 and PAX8 (Eccles et al., 1995).
This suggested that the nephron progenitor is a more promising target as the tumor initiating
cell than the stromal progenitor. The genes we genetically engineered have been shown to
be critical in functions of the nephron progenitors. Wt1 is essential for MET of the nephron
progenitor, thus when Wt1 is ablated, the progenitor can not go through MET but maintains
a progenitor status of self-renewing and proliferating. When Igf2 is simultaneously overexpressed, which promotes the metanephric mesenchymal cell to proliferate, the nephron
progenitor becomes fully transformed. β-catenin regulates the nephron progenitors in cell
survival, self-renewal, proliferation and differentiation (Schmidt-Ott and Barasch, 2008).
When the balances between these functions are disrupted by β-CATENIN stabilization, the
nephron progenitor cells are transformed. However, we can not rule out the possibility that
the nephron progenitor cells are partially transformed when they are targeted with the
genetic alterations and that the mutated cells persist. They become completely tumorigenic
until a later stage when they gain further epigenetic alterations or when they are affected by
microenvironment changes.

4.4 Wilms tumors with the nephron progenitor origin targeted with Six2GCE or Cited1Cre
We targeted the nephron progenitor by using two Cre lines, Six2GCE and Cited1Cre.
CITED1 is expressed in the uninduced nephron progenitor that has the capability of selfrenewal and resistance to differentiation. SIX2 is expressed in the uninduced nephron
progenitor and also the induced nephron progenitor that responds to WNT9b-β-CATENIN
signaling and starts to undergo MET. A subset of SIX2-expressing cells also expresses
CITED1. Both Cited1 and Six2 are markers for the multipotent and self-renewing nephron
progenitors, but Cited1 is not essential for nephrogenesis because Cited1 deletion in mice
does not affect kidney development (Boyle et al., 2007). Six2 is required for the
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maintenance of self-renewal of nephron progenitors (Self et al., 2006). We took advantage
of the availability of Cited1Cre and Six2GCE mouse lines and incorporated a flox allele of the
gene of interest to target mutations to the nephron progenitors.
The difference between the Cited1Cre and Six2GCE Cres is that the Cited1Cre is a
transgene while Cited1 and Six2 genes are wild type, whereas Six2GCE is a knock-in allele,
resulting in Six2 is haploinsufficiency. When we targeted Wt1 ablation into the nephron
progenitors with Cited1Cre (C-Wt1-Igf2), triphasic Wilms tumors developed, but tumors did
not develop in S-Wt1-Igf2 mutants. The difference between the Cited1Cre+ cells and the
Six2GCE+ cells is that they have different gene dosages of Six2. Six2 has been shown to be
essential for the self-renewal of nephron progenitors (Kobayashi et al., 2008). Moreover, in
human Wilms tumors, SIX2 is expressed in blastemal elements of tumors (Murphy et al.,
2012), and overexpression of SIX2 in a human Wilms tumor cell line enhanced cell survival,
proliferation and migration of tumor cells (Pierce et al., 2014; Senanayake et al., 2013).
Overexpression of Six2 repressed differentiation directed by Tcf/Lef dependent Wnt
signaling and promoted the stemness facilitated by Survivin dependent Wnt signaling
(Pierce et al., 2014). It is possible that in the genetic context of Wt1-Igf2, wild type Six2
expression and Wt1 ablation synergistically contributed to cell transformation, and
haploinsufficiency of Six2 in Six2GCE+ cells prevented cells from being tumorigenic. Thus,
the Six2GCE+ cells were not as sensitive as the Cited1Cre+ cells were to the oncogenic effects
of Wt1 ablation.
However, both Cited1Cre+ cells and Six2GCE+ cells were able to give rise to Wilms tumors
when β-CATENIN was stabilized. This indicates that in the case of β-CATENIN stabilization,
Six2 gene dosage (Wild type in Cited1Cre+ cells or haploinsufficient in Six2GCE+ cells) did not
affect the malignant competency of nephron progenitors. Moreover, phenotypically,
molecularly, and immunohistochemically, tumors targeted by both Cre alleles, Cited1Cre or
Six2GCE, are very similar. Both the Cited1Cre and Six2GCE tumors histologically showed a
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primitive epithelial type of Wilms tumor and were associated with kidney cyst phenotype.
qRT-PCR and IHC analysis showed the Cited1Cre and Six2GCE tumors had a similar
expression profile of differentiation markers. The unsupervised clustering of RPPA results
with Cited1Cre and Six2GCE tumors did not show a difference in the protein expression level of
the oncoproteins and tumor suppressors in the canonical cancer signaling pathway that
were included in the RPPA assay. Since both Cited1Cre and Six2GCE targeted the nephron
progenitors, it is not surprising that they resulted in similar type of Wilms tumors.

4.5 Wt1 is not required for tumor development once β-CATENIN is stabilized in
nephron progenitors
When β-CATENIN stabilization was targeted into the nephron progenitors with either
Six2GCE or Cited1Cre, tumors developed, despite the fact that these tumor mice carried
different genotypes of Wt1, eg. Wt1-/fl, Wt1+/fl, or Wt1+/+. Moreover, in nephron progenitors
with β-catS, the Wt1 floxed allele was either completely or partially recombined, suggesting
that Wt1 status is not relevant in tumorigenesis when β-catenin is stabilized in nephron
progenitors. In particular, the mutant mice with Wt1+/+ developed tumors and all these
tumors had β-catS, confirming that β-catenin stabilization is sufficient to transform nephron
progenitors. Furthermore, qPCR, IHC and RPPA analysis of the tumors with differential
gene dosage of Wt1 showed very similar histology and expression profiles of marker genes
and cancer signaling proteins between these tumors. However, in human Wilms tumors, βCATENIN stabilization mutations are exclusively associated with WT1 loss of function
mutations, and WT1 mutations and β-CATENIN mutations occurred in sequence during
tumor progression (Maiti et al., 2000) (Fukuzawa et al., 2007). It is because of these findings
that we initially designed the experiments by combining Wt1 ablation together with β-catenin
stabilization and engineered them genetically into mouse embryo kidney cells. The different
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roles of Wt1 in tumor development between mice and humans could be explained by the
differences in the developmental process between mice and humans.

4.6 Within the nephron progenitor cell origin, different genetic lesions generated
different tumor types
With the nephron progenitor cell origin, we found that different sets of mutations (Wt1-βcatS and Wt1-Igf2) generated different types of Wilms tumors. Wt1-β-catS tumors and Wt1Igf2 tumors had a similar tumor onset, penetrance of tumor occurrence and tumor
proliferation profile. But Wt1-Igf2 tumors did not have the cystic kidney phenotype that we
observed in Wt1-β-catS tumors. Expression analysis of differentiation markers showed that
Wt1-β-catS tumors were more epithelially differentiated, while the Wt1-Igf2 tumors were
more mesenchymal.
Wt1-β-catS tumors were characterized by a differentiated epithelial histology, composed
mainly of epithelial cells forming tubule-like structures surrounded by stromal cells. These
tumor epithelial cells expressed the epithelial differentiation marker E-CADHERIN, which
was not expressed in the Wt1-Igf2 tumors. Interestingly, these epithelial tumor cells also
showed expression of the nephron progenitor markers CITED1 and SIX2 and the
mesenchymal stem cell marker DLK1, suggesting that these cells were abnormally
differentiated and retained features of their progenitor cell origin. In addition, Wt1-β-catS
tumors expressed muscle differentiation markers, suggesting that a muscle cell
differentiation program was likely activated by β-CATENIN stabilization. However, they did
not express intermediate mesenchyme markers (Eya1, Hoxa11 and Osr1), renal
mesenchyme markers (Pax2 and NCAM) and precursor epithelial markers for renal vesicle
(Wnt4, CyclinD1 and Jag1) as Wt1-Igf2 tumors did.
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By contrast, Wt1-Igf2 tumors displayed a triphasic histology, comprised dominantly of
undifferentiated blastemal cells, differentiated epithelial cells and stromal cells. Wt1-Igf2
tumors showed high expression of genes upregulated in nephron progenitor (Cited1, Six2
and Pax2) and in renal vesicle (Wnt4, CyclinD1 and Jag1). This expression profile correlates
with the histology of blastemal and differentiating epithelial elements in the tumors.
Moreover, genes corresponding to intermediate mesenchyme (Eya1, Hoxa11 and Osr1)
were highly expressed in Wt1-Igf2 tumors. Overexpression of the transcription factors Six2,
Eya1, Hoxa11, Osr1 and Snail2 in differentiated proximal tubule cells was sufficient to
reprogram cells to nephron progenitor cells (Hendry et al., 2013). Thus, we propose that the
transformed cells in Wt1-Igf2 tumors may have undergone dedifferentiation and acquired
increased ability of self-renewal and multipotency. Furthermore, Wt1-Igf2 tumors showed
elevated expression of genes involved in muscle differentiation such as Ttn and Actin-a1,
demonstrating an enhanced plasticity in differentiation capabilities in tumor cells like in the
intermediate mesenchyme.
The molecular and immunohistochemical analysis of mouse tumors indicated that the
differentiation program of the tumor-initiating cells was influenced by the genetic lesions of
Wt1-Igf2 or Wt1-β-catenin, which is likely related to the functions of the genes in nephron
progenitors for normal renal development.

4.7 Gene mutations impact dominantly on the formation of different types of mouse
WTs
Wt1 and β-catenin are both critical in regulating the functions and differentiation of the
nephron progenitors. When one or more of them are deregulated, the resulting signaling can
become oncogenic and facilitate cell transformation, and at the same time, it can affect the
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cell differentiation program by either directing cells to dedifferentiate or to differentiate
ectopically.
Wt1 is required for MET (Hu et al., 2010). Wt1 deletion prevented the nephron progenitor
cells from differentiating, but preserved progenitor cells in a self-renewing and stem-like
state. A very recent study found that at E11.5 and E15.5, at the periphery of the CM, there
were rarely cells expressing both SIX2 and FOXD1 and that these few cells with dual
identities could be fated toward either the stromal or epithelial cell types (Brunskill et al.,
2014). Therefore, it is possible that the Wt1-Igf2 mutant nephron progenitor cells could
dedifferentiate to an earlier lineage such as the SIX2-FOXD1 dual identity state or even an
earlier state, such as intermediate mesenchyme. In addition to the partial transformation
resulting from Wt1 deletion, the Igf2 overexpression that promoted cell proliferation caused
the progenitor cells to fully transform into tumor cells with a broad differentiation potential.
Wnt/β-catenin signaling has been shown to be essential for nephron progenitors to
survive, proliferate, and self-renew (Park et al., 2007). WNT9b signaling from the ureteric
bud induces the undifferentiated and uninduced nephron progenitor cells to differentiate via
activation of the canonical β-CATENIN signaling pathway (Schmidt-Ott and Barasch, 2008).
However, when the cells further differentiate, β-CATENIN signaling activity must be reduced
for full epithelialization (Kuure et al., 2007). Our study demonstrated that constant activation
of β-catenin signaling was not only sufficient to transform nephron progenitor cells but also
biased the tumorigenic cells towards epithelial differentiation, thus generating the primitive
epithelial type of WTs. Moreover, we observed a strong association of kidney cyst formation
with the epithelial tumors and we speculated that β-CATENIN stabilization may disrupt cell
adhesion formation or cilia formation and increase the cytokinesis of the tumor cells.
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4.8 Comparison of tumor models in this study and published mouse WT models
The first Wilms tumor mouse model was generated by using a ubiquitous tamoxifeninducible Cre to somatically and mosaically ablate Wt1 together with systematic overexpression of Igf2 (UbCre-Wt1-Igf2). In this model, about 64% of mutants developed tumors
by the age of 19 weeks (Hu et al., 2010). The UbCre-Wt1-Igf2 tumors had triphasic histology
and showed activated extracellular signal-regulated kinase (ERK) signaling. In our C-Wt1Igf2 mouse model targeted by Cited1Cre, the tumors developed at 70 weeks old with a
frequency of 50% of the mutant mice. The C-Wt1-Igf2 tumors also had a triphasic histology
similar to the UbCre-Wt1-Igf2 tumors. The differences in tumor latency between the UbCreWt1-Igf2 mutants and the C-Wt1-Igf2 mutants may result from the different targeting
strategies with Cre expression driven by different promoters. In the UbCre-Wt1-Igf2 model,
kidney cells were targeted at E11.5. At E11.5, Wt1 is expressed in the metanephric
mesenchyme mainly composed of the nephron progenitors, stromal progenitors, and
possibly some other un-identified progenitor cell types (Mugford et al., 2009). Thus, all these
cell types could serve as candidate targets for tumor cell transformation. However, in our CWt1-Igf2 model, only the uninduced nephron progenitors were targeted at E14.5. We
speculated that in the UbCre-Wt1-Igf2 model, a cell population at an earlier lineage than the
nephron progenitor was targeted by the ubiquitous Cre. This stem cell population had a
higher capacity of proliferation and self-renewal than the nephron progenitor and led to
faster expansion of the transformed cells and thus an earlier tumor onset in UbCre-Wt1-Igf2
mice. There was a higher content of blastemal cells and a lower content of epithelial cells in
the histology of UbCre-Wt1-Igf2 tumors than that in the C-Wt1-Igf2 tumors. This observation
may also reflect our speculated stem cell origin of the UbCre-Wt1-Igf2 tumors versus the
lineage restricted nephron progenitor cell origin of the C-Wt1-Igf2 tumors. Cells targeted by
the UbCre could include the CITED1+ nephron progenitors, so the tumor spectrum of UbCreWt1-Igf2 tumors should include tumors like the C-Wt1-Igf2 tumors. Indeed, we observed that
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some of the UbCre-Wt1-Igf2 tumors histologically appeared very similar to the C-Wt1-Igf2
tumors.
Later, another mouse model was reported in which mini-primitive epithelial WTs
developed with the use of Cited1Cre to stabilize β-CATENIN with or without Kras activation
postnatally (C-β-catS-Kras) (Clark et al., 2011). In this model, a proximal tubule specific γGTCre was also used to stabilize β-CATENIN and activate Kras (γGTCre-β-catS-Kras) and the
development of the same epithelial WTs was detected as was the case with the C-β-catSKras tumors. The C-β-catS-Kras and γGTCre-β-catS-Kras tumors looked histologically very
similar to our S/C-Wt1-β-catS and S-β-catS tumors. However, our mouse tumors had a cystic
kidney phenotype that was absent in C-β-catS-Kras and γGTCre-β-catS-Kras tumors. In our
mouse models, the Six2GCE or Cited1Cre was activated by tamoxifen at an early stage of
kidney development (E14.5 or E17.5) to target the nephron progenitors, which was different
from the C-β-catS-Kras and γGTCre-β-catS-Kras models where cells were targeted at the postnatal stage, when CITED1+ nephron progenitor cells were depleted and γGT+ cells were fully
differentiated. It was likely that the γGT+ tubule cells underwent dedifferentiation when they
had β-catenin and Kras activation during the cell transformation process. Altogether, with βCATENIN stabilization, both multipotent nephron progenitors and completely differentiated
proximal tubules presented the capacity to give rise to epithelial WTs, suggesting that similar
type of WTs can be generated from diverse sources of cell origins.
Very recently, overexpression of a heterochronic regulator Lin28 in primordial germ cells
but not in nephron or stromal progenitors generated Wilms tumor (Urbach et al., 2014). This
suggested that different types of cells at different lineages can serve the cell origins of WTs
but that the malignant potentials depended on the context of the genetic alterations.
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4.9 Comparison of tumor models with human WT subsets
To correlate the mouse tumors with the identified 5 subsets of human WTs (Gadd et al.,
2012), we selected a few significant genes differentiating the human tumor subsets. We
compared the expression patterns of these genes in the different mouse tumor types with
the intent of determining whether these expression patterns were consistent with any of the
human tumor subsets.
S1 tumors are characterized by epithelial tubular differentiated histology without muscle
differentiation. S1 tumors had low expression of genes in early metanephric mesenchyme
but expressed genes in the post-induction stage of nephron and mature epithelium. S2-S5
tumors showed triphasic histology with varying degree of skeletal muscle differentiation, and
molecularly S2-S5 tumors were similar to one another. S2 tumors had loss of Wt1
expression and Wnt activation, and genes enriched in S2 corresponded to the differentiation
stage before mesenchyme induction (e.g. intermediate mesenchyme) and to kidney
interstitium. Compared to S2 tumors, S3 also had low Wt1 expression, but the expression of
skeletal muscle differentiation genes were lower and activity of canonical signaling such as
Wnt, Tgfβ, NFAT and Ras pathways was lower. S4 tumors were also very similar to S2
tumors in gene expression pattern, but showed less evidence of Wt1 loss of expression and
Wnt activation. S5 tumors expressed genes corresponding to early metanephric
mesenchyme.
The epithelial histology of S/C-Wt1-β-catS and S-β-catS tumors were like the S1 tumors
except that there are no β-catenin mutations in S1. However, the C-Wt1-Igf2 tumors showed
triphasic histology, which mimicked S2-S5 tumors histologically.
The genes that we checked in mouse tumors included genes in intermediate
mesenchyme before nephron induction, muscle differentiation and Wnt signaling. The
mesenchymal marker genes (Hoxa11, HMGA2 and Dlk1) that were expressed significantly
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lower in β-catS mouse tumors than the C-Wt1-Igf2 tumors were also expressed lower in S1
tumors than other subtypes. Therefore we thought that β-catS tumors may mimic S1 not only
histologically but also in gene expression, and that C-Wt1-Igf2 tumors may correlate to
certain subset among S1-S5. For the genes involved in muscle differentiation such as Pitx2,
Ttn and Actin-a1, the β-catS tumors and the C-Wt1-Igf2 tumors had similar expression level,
which was also observed between S1, S3 and S5. S3 tumors had low expression of Wt1,
less Wnt activation and high expression of Igf2, so we speculated that C-Wt1-Igf2 tumors
could be more related to S3 tumors. For the expression of Wnt/β-catenin inhibitor Wif1, βcatS tumors had higher expression than the Wt1-Igf2 tumors, which was not the case
between S1 and the other subsets, probably due to the lack of β-catenin mutations in S1
tumors. Together, based on these very preliminary data, we speculated that the β-catS
tumors may correspond to S1, while C-Wt1-Igf2 tumors may be related to S3. However,
further analysis such as microarray, cross-species comparison and clustering will be
required to define the correlation between the mouse models and the human tumor subsets.

4.10 Wt1 function in kidney development
Functional mutations of WT1 have been found in 20% of Wilms tumor patients. To
understand the mechanisms by which WT1 loss of function predisposes to malignant
transformation, it is important to understand WT1 function in kidney development. Wt1 is
expressed in the metanephric mesenchyme, mainly containing stromal and nephron
progenitors at an early stage of kidney development. Therefore, we used a high dose of
tamoxifen to ablate Wt1 in a high proportion of progenitor cells to study the effects of Wt1
ablation on nephrogenesis.
We found that Wt1 ablation in stromal progenitors (FOXD1+) did not seem to affect
kidney development. The F-Wt1 mutant kidneys appeared normal phenotypically and
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histologically. Cell tracking with a β-gal reporter showed that the stromal progenitor derived
cells with Wt1 ablation could differentiate and persisted in the adult kidney. A previous study
showed that FOXD1+ stromal progenitors gave rise to FLK1+ endothelial progenitors and
contributed partially to the vasculature patterning of the kidney (Sims-Lucas et al., 2013). An
in vitro culture study showed, at the periphery of embryonic kidney where the stromal
progenitors reside, FLK1+ angioblast mesenchyme expressed Wt1 and Wt1-stimulated
Vegfa signaling was essential to initially induce but not required to sustain the differentiation
of the MM and the outgrowth and branching of the ureteric bud (Gao et al., 2005). These
studies suggested that Wt1 in stromal progenitors could regulate the mesenchyme-ureteric
bud interaction. However, our in vivo mouse model with Wt1 ablation in stromal progenitors
did not show a defect in nephrogenesis. The different outcomes between our findings and
the previous study of Wt1 in angioblasts could be due to the differences in using an in vivo
genetic model in our study versus using the in vitro culture method employed in the previous
study, or because we ablated Wt1 at a stage which has passed the time for the requirement
of angioblast-mesenchyme for initial induction of nephrogenesis.
When Wt1 was ablated in nephron progenitors (SIX2+), the nephrogenic zone (NZ),
where the progenitors reside, was expanded with increased numbers of cells condensing
and surrounding the ureteric buds. The cells in the expanded NZ were proliferative and
expressed the nephron progenitor markers (CITED1 and PAX2), confirming their nephron
progenitor identity. The mutant kidneys expressed significantly higher levels of the marker
for intermediate mesenchyme, Osr1, than did the normal kidneys, suggesting that Wt1
ablation may have reprogramed nephron progenitors to an OSR1+ cell state which is an
earlier lineage than the nephron progenitor. This could explain the presence of ectopic
skeletal elements in the human tumors with loss of Wt1 function mutations, which may result
from the gained differentiation plasticity of the tumor cells. The gained multipotency and
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long-term self-renewal caused the Wt1-ablated mutant cells to become partially transformed
and be good candidates for transformation once another oncogenic event occurred.
Furthermore, in the S-Wt1 mutant kidneys, nephrogenesis was blocked. The disrupted
nephrogenesis phenotype appeared as early as at E15.5 in the mutant kidneys. The results
with S-Wt1 mutant kidneys indicated that Wt1 ablation in the nephron progenitors prevented
the cells from differentiating but sustained the undifferentiated state of the nephron
progenitor. This result was consistent with the findings of previous studies. When Wt1 was
ablated at E11.5 using a ubiquitous Cre, the metanephric mesenchyme did not condense
and the MET process was blocked (Hu et al., 2010). Knock-down of Wt1 using siRNA in
mouse embryonic kidney rudiment in vitro also showed abnormal cell proliferation and
disrupted cell epithelial differentiation (Davies et al., 2004).
Deletion of another Wilms tumor suppressor, Wtx, also presented a similar phenotype in
neonatal kidneys (Moisan et al., 2011). Although Wtx-/- kidneys showed normal
nephrogenesis, they had expanded pools of aggregates of SIX2+ cells and altered cell fate
commitment and delayed differentiation in mesenchymal progenitor cells (Moisan et al.,
2011). The defects in cell fate determination were regulated by abnormal activation of βcatenin signaling (Moisan et al., 2011). Interestingly, in our Wt1 ablated mutant kidneys, the
expression of Axin2 (the effector of WNT/β-CATENIN signaling) was significantly higher than
the normal kidneys, suggesting that β-catenin activation may also be involved in the defects
in cell differentiation of nephron progenitors that were caused by Wt1 ablation. Wnt4 was
identified as a Wt1 transcriptional target to promote the MET (Sim et al., 2002), but in our
study Wnt4 was not differentially expressed between the S-Wt1 mutant kidneys and the
normal kidneys.
In addition, S-Wt1 mutant kidneys from 1 month and 2.5 months old mutant mice
showed a thinner cortex and multiple fibrotic lesions. However, it was unknown whether
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these fibrotic cells were derived from Wt1 ablated nephron progenitor or whether they were
a secondary response to signaling caused by Wt1 ablated but phenotypically normal cells in
the kidney. β-gal reporter tracking of Wt1 ablated cells showed that the cells in the fibrotic
lesions did not express β-gal, suggesting that the lesional cells may not come from nephron
progenitors, although this result could also have been caused by the scarcity of cytoplasm in
the lesion cells which was insufficient to visualize β-gal staining. Lack of the expression of
nephron progenitor markers SIX2, CITED1 and precursor epithelial marker K-CADHERIN in
these cells suggested these cells were not persisting progenitor cells or abnormally
differentiating epithelial cells. F4/80 staining showed that these cells were not infiltrating
inflammatory cells. Ubiquitous deletion of Wt1 in adult mice also showed no systemic
inflammatory response in the mutant although the mutant had acute multiple organ failure
due to disturbed tissue homeostasis (Chau et al., 2011). In the adult S-Wt1 adult mice, the
cells in the lesions were proliferative. VIMENTIN and COLLAGEN IV staining showed that
these cells were mesenchymal and Masson’s Trichrome staining confirmed these cells were
associate with fibrotic tissue. Increased COLLAGEN IV expression indicated TGFβ signaling
may be involved. Further analysis of IHC and qPCR needs to be done to identify the
dysregulated signaling pathway resulting in fibrosis formation.
Our study of ablating Wt1 in nephron progenitors has shown that Wt1 promotes the
nephron progenitors to differentiate and that loss of Wt1 sustains the long-term self-renewal
capability and multipotency of the lineage-restricted nephron progenitors, making these cells
good targets for cell transformation.
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Conclusion and Significance
In conclusion, we investigated the cell origin of Wilms tumor and the effects of genetic
mutations on formation of different tumor types by using mouse genetic models. Our study
has demonstrated that during kidney development the nephron progenitors can give rise to
Wilms tumors with Wt1-Igf2 or β-catenin mutations but the stromal progenitors are not at risk
of tumor development with these genetic alterations. With the nephron progenitor cell origin,
Wt1-β-catS tumors and Wt1-Igf2 tumors had similar profiles in tumor latency and tumor
frequency. However, the type of gene mutations affects the differentiation program of the
transformed cells, thus resulting in different types of tumors. The Wt1-β-catS mutations
resulted in epithelial differentiated Wilms tumors, whereas the Wt1-Igf2 alterations led to
more mesenchymal Wilms tumors. Moreover, we characterized the effects of Wt1 ablation in
the stromal and nephron progenitors on kidney development in order to understand the
mechanisms by which Wt1 inactivation mutations predispose to WTs. Wt1 does not seem to
be critical in stromal progenitors, but in nephron progenitors Wt1 is essential for the
mesenchyme to epithelial transition and may regulate the dedifferentiation program of
nephron progenitors.
Wilms tumor is genetically and histologically heterogeneous. Understanding the impact
of the differentiation status of tumor initiating cells on resulting tumor biology and the effects
of gene mutations on the formation of different tumor types can provide significant insights
into the mechanisms of the tumorigenic processes. Knowledge of the functions of Wt1 in
renal progenitors will further help us to understand how Wt1 mutations transform the
progenitors to tumor cells.
Wilms tumor patients are sometimes treated with chemotherapy and radiation therapy,
which can cause side effects and place them at risk for a secondary tumor later in life.
Targeted therapies are needed to help reduce such side effects while providing effective
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treatment. The mouse models of different types of Wilms tumors provide a useful tool for the
identification of the biomarkers associated with different tumor types and tumor stages. With
the development of new tumor biomarkers, we can detect tumors at an earlier stage and we
also can stratify patients according to their biomarker profiles and apply specific treatment
strategies to specific tumor subsets. Moreover, the mouse models can be used to identify
druggable protein targets which are the key regulators in Wilms tumorigenesis and used to
screen and test drugs for the best efficacy for treating tumors with minimum side effects.
The preclinical models can be utilized for the development of improved therapy for the
ultimate benefits of these young patients.
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Future directions
A complete understanding of the tumor initiation process is important in preventing tumor
development. Fluorescent protein reporter and sensitive imaging techniques are great tools
to track Wilms tumor initiating cells to monitor the early stages of tumor development and
tumor progression. These methods can be used to detect the presence of Wilms tumor
precursor lesions and monitor when and how the lesions progress to tumors. Our mouse
models have shown that tumors arising from the same nephron progenitor origin are
different in histology, gene expression profile and differentiation status due to the different
genetic mutations induced. Therefore it is interesting to investigate how these genetic
alterations affected the formation of different types of tumors. With the tool of the reporter
tracking tumorigenic cells, the pathological process can be monitored by analyzing the
reporter labeled cells with the examination of histology, co-staining with antibodies for
differentiation markers and cancer signaling regulators. Not only can we study how the
tumor cells differentiate, but we also can investigate how the tumor cells interact with the
tumor microenvironment. Moreover, tumor precursor lesions or small tumors at an early
stage can be isolated with FACS of the fluorescent protein labeled mutant cells in order to
allow gene expression and protein expression analysis of these cells. To examine tumor cell
aggressiveness and metastatic potential, the isolated tumor cells can be injected as
xenografts to test transplanted tumor growth and metastatic ability.
To understand the molecular mechanisms of the development of different types of
mouse Wilms tumors, microarray of the tumors can be performed to characterize the global
gene expression patterns between the types of mouse tumors. These data can be analyzed
with Ingenuity Pathway Analysis (IPA) to determine genes and pathways that are
significantly differentially expressed between the different types of tumors. The expression
profiles of mouse models then can be compared to the expression data of human subsets
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with cross-species analysis and clustering of the results can be performed to find out
whether there is an association of the mouse WTs with the human subsets. Potentially, with
this bioinformatics information, drug targets and the biomarkers differentiating these tumor
types may be identified. Thus this will help to develop targeted therapies for patients and
potentially avoid the long-term side effects from chemotherapy and radiation.
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